☰

C. David Marsden - Publications

Affiliations: 
Neurology King's College (London), London, England, United Kingdom 
Tree Info Grants Similar researchers PubMed Report error

61/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
1998 Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 55: 23-30. PMID 9483167 DOI: 10.2165/00003495-199855001-00004  0.56
1997 Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology. 48: 363-8. PMID 9040722 DOI: 10.1212/Wnl.48.2.363  0.549
1996 Smith L, De Salvia M, Jenner P, Marsden CD. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 125-35. PMID 8684381 DOI: 10.1002/Mds.870110203  0.321
1995 Gnanalingham KK, Jenner P, Hunter AJ, Marsden CD. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology. 117: 287-297. PMID 7770604 DOI: 10.1007/Bf02246103  0.316
1992 Burn DJ, Mark MH, Playford ED, Maraganore DM, Zimmerman TR, Duvoisin RC, Harding AE, Marsden CD, Brooks DJ. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology. 42: 1894-900. PMID 1407569 DOI: 10.1212/Wnl.42.10.1894  0.483
1992 Lange KW, Löschmann PA, Wachtel H, Horowski R, Jähnig P, Jenner P, Marsden CD. Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. European Journal of Pharmacology. 212: 247-52. PMID 1350996 DOI: 10.1016/0014-2999(92)90337-4  0.3
1990 Rose S, Nomoto M, Jenner P, Marsden CD. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochemical Pharmacology. 38: 3677-81. PMID 2597167 DOI: 10.1016/0006-2952(89)90572-8  0.407
1989 Temlett JA, Chong PN, Oertel WH, Jenner P, Marsden CD. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. European Journal of Pharmacology. 156: 197-206. PMID 2977118 DOI: 10.1016/0014-2999(88)90322-6  0.365
1989 Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 261-5. PMID 2571082 DOI: 10.1002/mds.870040307  0.302
1989 Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neuroscience Letters. 101: 305-310. PMID 2505199 DOI: 10.1016/0304-3940(89)90550-8  0.392
1988 Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Advances in Neurology. 50: 377-84. PMID 3041760  0.483
1987 De Ceballos ML, Boyce S, Jenner P, Marsden CD. Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats. European Journal of Pharmacology. 130: 305-9. PMID 3792452 DOI: 10.1016/0014-2999(86)90282-7  0.387
1987 Dewar D, Jenner P, Marsden CD. Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of rat globus pallidus. Biochemical Pharmacology. 36: 1738-1741. PMID 3297065 DOI: 10.1016/0006-2952(87)90062-1  0.307
1987 Kelly E, Jenner P, Marsden CD. Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats. The Journal of Pharmacy and Pharmacology. 39: 196-202. PMID 2883284 DOI: 10.1111/J.2042-7158.1987.Tb06248.X  0.415
1986 Simpson MDC, Jenner P, Marsden CD. Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat Biochemical Pharmacology. 35: 3501-3506. PMID 3768037 DOI: 10.1016/0006-2952(86)90618-0  0.366
1986 Simpson MDC, Jenner P, Marsden CD. Hyperprolactinaemia does not alter specific striatal 3H-spiperone binding in the rat Biochemical Pharmacology. 35: 3203-3208. PMID 3768017 DOI: 10.1016/0006-2952(86)90414-4  0.352
1986 Jenner P, Marsden CD. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Journal of Neural Transmission. Supplementum. 20: 11-39. PMID 3091760  0.327
1986 Nomoto M, Jenner P, Marsden CD. Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset. European Journal of Pharmacology. 121: 123-8. PMID 3082655 DOI: 10.1016/0014-2999(86)90401-2  0.376
1986 Quinn N, Critchley P, Parkes D, Marsden CD. When should levodopa be started? Lancet (London, England). 2: 985-6. PMID 2877169 DOI: 10.1016/S0140-6736(86)90642-2  0.337
1985 Rupniak NM, Hall MD, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden CD. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochemical Pharmacology. 34: 2755-63. PMID 4040370 DOI: 10.1016/0006-2952(85)90577-5  0.395
1985 Kelly E, Jenner P, Marsden CD. The effects of dopamine and dopamine agonists on the release of 3H-GABA and 3H-5HT from rat nigral slices. Biochemical Pharmacology. 34: 2655-62. PMID 3925957 DOI: 10.1016/0006-2952(85)90563-5  0.345
1984 Boyce S, Kelly E, Reavill C, Jenner P, Marsden CD. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Biochemical Pharmacology. 33: 1747-52. PMID 6610420 DOI: 10.1016/0006-2952(84)90344-7  0.41
1984 Rupniak NMJ, Jenner P, Marsden CD. Enhancement of stereotypy induced by nomifensine in rats during continuous chronic haloperidol treatment Neuroscience Letters. 50: 63-65. PMID 6541767 DOI: 10.1016/0304-3940(84)90463-4  0.37
1984 Jenner P, Rupniak NM, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neuroscience Letters. 50: 85-90. PMID 6436758 DOI: 10.1016/0304-3940(84)90467-1  0.411
1984 Kerwin R, Rupniak NMJ, Jenner P, Marsden CD. Functional increase in striatal dopaminergic activity following continuous long-term treatment with trifluoperazine Neuroscience Letters. 45: 329-334. PMID 6145129 DOI: 10.1016/0304-3940(84)90247-7  0.334
1984 Kilpatrick GJ, Jenner P, Marsden CD. The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes European Journal of Pharmacology. 107: 71-78. PMID 6084599 DOI: 10.1016/0014-2999(84)90093-1  0.36
1983 Murugaiah K, Fleminger S, Theodorou A, Jenner P, Marsden CD. Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake Biochemical Pharmacology. 32: 2495-2499. PMID 6684429 DOI: 10.1016/0006-2952(83)90008-4  0.367
1983 Reavill C, Jenner P, Marsden CD. Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways. Biochemical Pharmacology. 32: 865-870. PMID 6301501 DOI: 10.1016/0006-2952(83)90589-0  0.388
1983 Hall MD, Jenner P, Marsden CD. Differential labelling of dopamine receptors in rat brain in vivo: comparison of [3H]piribedil, [3H]S 3608 and [3H]N,n-propylnorapomorphine. European Journal of Pharmacology. 87: 85-94. PMID 6188621 DOI: 10.1016/0014-2999(83)90053-5  0.367
1982 Taylor RJ, Reavill C, Jenner P, Marsden CD. Circling behavior following unilateral kainic acid injections into rat striatum. European Journal of Pharmacology. 76: 211-22. PMID 7333356 DOI: 10.1016/0014-2999(81)90503-3  0.315
1982 Jenner P, Hall MD, Murugaiah K, Rupniak N, Theodorou A, Marsden CD. Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity Biochemical Pharmacology. 31: 325-328. PMID 7200363 DOI: 10.1016/0006-2952(82)90178-2  0.408
1982 Jenner P, Rupniak NM, Hall MD, Dyer R, Leigh N, Marsden CD. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment. European Journal of Pharmacology. 76: 31-6. PMID 6119220 DOI: 10.1016/0014-2999(81)90006-6  0.397
1981 Barbeau A, Duvoisin RC, Gerstenbrand F, Lakke JP, Marsden CD, Stern G. Classification of extrapyramidal disorders. Proposal for an international classification and glossary of terms. Journal of the Neurological Sciences. 51: 311-27. PMID 7276982 DOI: 10.1016/0022-510X(81)90109-X  0.412
1980 Marsden CD, Duvoisin R. Scoliosis and Parkinson's Disease Jama Neurology. 37: 253-254. PMID 7362496 DOI: 10.1001/Archneur.1980.00500530091025  0.532
1978 Bédard P, Parkes JD, Marsden CD. Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. British Medical Journal. 1: 954-6. PMID 638546 DOI: 10.1136/bmj.1.6118.954  0.308
1978 Pycock CJ, Marsden CD. The rotating rodent: a two component system? European Journal of Pharmacology. 47: 167-75. PMID 340238 DOI: 10.1016/0014-2999(78)90388-6  0.414
1978 Jenner P, Pycock C, Marsden CD. The effect of chronic administration and withdrawal of amphetamine on cerebral dopamine receptor sensitivity. Psychopharmacology. 58: 131-6. PMID 98779 DOI: 10.1007/Bf00426895  0.303
1978 Dolphin A, Jenner P, Marsden CD. 3-Methoxy-4-hydroxyphenylglycol sulphate (MOPEG-SO4) as an index of cerebral noradrenaline turnover following depletion of transmitter stores in the rat. The Journal of Pharmacy and Pharmacology. 30: 580-2. PMID 29100 DOI: 10.1111/J.2042-7158.1978.Tb13329.X  0.406
1977 Sawaya MC, Dolphin A, Jenner P, Marsden CD, Meldrum BS. Noradrenaline-sensitive adenylate cyclase in slices of mouse limbic forebrain: characterisation and effect of dopaminergic agonists. Biochemical Pharmacology. 26: 1877-84. PMID 911341 DOI: 10.1016/0006-2952(77)90161-7  0.499
1977 Dolphin A, Christina M, Sawaya MC, Jenner P, Marsden CD. Behavioural and biochemical effects of chronic reduction of cerebral noradrenaline receptor stimulation. Naunyn-Schmiedeberg's Archives of Pharmacology. 299: 167-73. PMID 909612 DOI: 10.1007/Bf00498559  0.52
1977 Donaldson IM, Dolphin AC, Jenner P, Pycock C, Marsden CD. Rotational behaviour produced in rats by unilateral electrolytic lesions of the ascending noradrenergic bundles. Brain Research. 138: 487-509. PMID 597720 DOI: 10.1016/0006-8993(77)90685-0  0.495
1977 Dolphin AC, Jenner P, Marsden CD, Sawaya MC. Central dopaminergic and noradrenergic components of bromocryptine-induced locomotor activity in mice [proceedings]. British Journal of Pharmacology. 59: 467P. PMID 576587  0.417
1977 Pycock CJ, Jenner PG, Marsden CD. The interaction of clonidine with dopamine-dependent behaviour in rodents. Naunyn-Schmiedeberg's Archives of Pharmacology. 297: 133-41. PMID 558529 DOI: 10.1007/BF00499922  0.31
1977 Dolphin AC, Jenner P, Sawaya MC, Marsden CD, Testa B. The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents. The Journal of Pharmacy and Pharmacology. 29: 727-34. PMID 22618 DOI: 10.1111/J.2042-7158.1977.Tb11450.X  0.501
1976 Dolphin A, Jenner P, Marsden CD. Modification of the L-DOPA reversal of reserpine akinesia by inhibitors of dopamine-beta-hydroxylase. European Journal of Pharmacology. 35: 135-44. PMID 1253815 DOI: 10.1016/0014-2999(76)90308-3  0.571
1976 Dolphin A, Jenner P, Marsden CD. Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity. Pharmacology, Biochemistry, and Behavior. 5: 431-9. PMID 1005491 DOI: 10.1016/0091-3057(76)90107-6  0.497
1976 Donaldson IM, Dolphin A, Jenner P, Marsden CD, Pycock C. The involvement of noradrenaline in motor activity as shown by rotational behaviour after unilateral lesions of the locus coeruleus. Brain : a Journal of Neurology. 99: 427-46. PMID 1000281 DOI: 10.1093/Brain/99.3.427  0.491
1976 Costall B, Marsden CD, Naylor RJ, Pycock CJ. The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain. Brain Research. 118: 87-113. PMID 990957 DOI: 10.1016/0006-8993(76)90843-X  0.305
1976 Dolphin AC, Jenner P, Marsden CD. The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice. Pharmacology, Biochemistry, and Behavior. 4: 661-70. PMID 981283 DOI: 10.1016/0091-3057(76)90217-3  0.511
1976 Donaldson I, Dolphin A, Jenner P, Marsden CD, Pycock C. The roles of noradrenaline and dopamine in contraversive circling behaviour seen after unilateral electrolytic lesions of the locus coeruleus. European Journal of Pharmacology. 39: 179-91. PMID 976315 DOI: 10.1016/0014-2999(76)90126-6  0.496
1976 Donaldson IM, Dolphin A, Jenner P, Marsden CD, Pycock C. Contraversive circling behaviour produced by unilateral electrolytic lesions of the ventral noradrenergic bundle mimicking the changes seen with unilateral electrolytic lesions of the locus coeruleus. The Journal of Pharmacy and Pharmacology. 28: 329-31. PMID 6733 DOI: 10.1111/J.2042-7158.1976.Tb04171.X  0.412
1975 Dolphin A, Jenner P, Marsden CD. Interference by alphamethylparatyrosine with three procedures for assay of cerebral catecholamines. Journal of Neurochemistry. 25: 897-8. PMID 1206407 DOI: 10.1111/J.1471-4159.1975.Tb04425.X  0.362
1975 Dolphin A, Jenner P, Marsden CD. Proceedings: Biochemical evidence for the involvement of noradrenaline in motor activity produced by L-DOPA in rodents. British Journal of Pharmacology. 55: 292P. PMID 1201420  0.447
1975 Duvoisin RC, Marsden CD. Note on the scoliosis of Parkinsonism Journal of Neurology, Neurosurgery and Psychiatry. 38: 787-793. PMID 1185199 DOI: 10.1136/jnnp.38.8.787  0.53
1975 Jenner P, Marsden CD. The influence of piribedil (ET495) on components of locomotor activity. European Journal of Pharmacology. 33: 211-215. PMID 1175688 DOI: 10.1016/0014-2999(75)90160-0  0.359
1975 Dolphin A, Jenner P, Marsden CD, Pycock C, Tarsy D. Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. Psychopharmacologia. 41: 133-8. PMID 1171487 DOI: 10.1007/Bf00421070  0.542
1975 Dolphin A, Jenner P, Marsden CD. Proceedings: The mechanism of the effect of dopamine-beta-hydroxylase inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia. British Journal of Pharmacology. 54: 246P-247P. PMID 1148534  0.471
1975 Duvoisin RC, Marsden CD. Alpha-methyldopamine as a dopaminergic agonist Advances in Neurology. 9: 243-248. PMID 1146655  0.468
1975 Marsden CD, Duvoisin RC, Jenner P, Parkes JD, Pycock C, Tarsy D. Relationship between animal models and clinical parkinsonism. Advances in Neurology. 9: 165-75. PMID 1146651  0.475
1974 Marsden CD, Dolphin A, Duvoisin RC, Jenner P, Tarsy D. Role of noradrenaline in levodopa reversal of reserpine akinesia. Brain Research. 77: 521-5. PMID 4854165 DOI: 10.1016/0006-8993(74)90643-X  0.589
1974 Duvoisin RC, Marsden CD. Reversal of reserpine-induced bradykinesia by a-methyldopa - new light on its modus operandi Brain Research. 71: 178-182. PMID 4821419 DOI: 10.1016/0006-8993(74)90204-2  0.436
Low-probability matches (unlikely to be authored by this person)
1985 Rupniak NM, Mann S, Hall MD, Fleminger S, Kilpatrick G, Jenner P, Marsden CD. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. Psychopharmacology. 84: 503-11. PMID 6441951 DOI: 10.1007/BF00431457  0.299
1977 Elliott PN, Jenner P, Huizing G, Marsden CD, Miller R. Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology. 16: 333-42. PMID 559256 DOI: 10.1016/0028-3908(77)90070-3  0.299
1998 Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 234-41. PMID 9539335 DOI: 10.1002/Mds.870130207  0.299
1989 Rose S, Nomoto M, Jackson EA, Gibb WRG, Jenner P, Marsden CD. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets. Neuropharmacology. 28: 1211-1216. PMID 2512516 DOI: 10.1016/0028-3908(89)90213-X  0.299
1988 Moser A, Reavill C, Liebetrau A, Jenner P, Marsden CD, Cramer H. Dopamine and somatostatin modulated adenylate cyclase activity in the rat caudate-putamen following unilateral cortical ablation. Experimental Brain Research. 68: 406-10. PMID 2891560 DOI: 10.1007/Bf00248805  0.298
1983 Anker L, Testa B, Van De Waterbeemd H, Bornand-Crausaz A, Theodorou A, Jenner P, Marsden CD. Basicity, Lipophilicity, and Lack of Receptor Interaction ofN-Aminoalkylbenzamides andN-Aminoalkyl-o-anisamides as Model Compounds of Dopamine Antagonists Helvetica Chimica Acta. 66: 542-556. DOI: 10.1002/Hlca.19830660215  0.298
1989 Rose S, Thomas K, Jenner P, Marsden CD. Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover British Journal of Pharmacology. 98: 816P. PMID 2611523  0.297
1989 Stewart BR, Jenner P, Marsden CD. Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs. European Journal of Pharmacology. 162: 101-7. PMID 2524394 DOI: 10.1016/0014-2999(89)90608-0  0.296
1984 Kelly E, Jenner P, Marsden CD. Behavioural effects mediated by unilateral nigral dopamine receptor stimulation in the rat. Experimental Brain Research. 55: 243-52. PMID 6611272 DOI: 10.1007/Bf00237275  0.296
1983 Luscombe G, Jenner P, Marsden CD. Alterations in brain 5HT and tryptamine content during indoleamine-induced myoclonus in guinea pigs Biochemical Pharmacology. 32: 1857-1864. PMID 6192824 DOI: 10.1016/0006-2952(83)90050-3  0.296
1985 Rupniak NM, Kilpatrick G, Hall MD, Jenner P, Marsden CD. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology. 84: 512-9. PMID 6441952 DOI: 10.1007/Bf00431458  0.294
1991 Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Archives of Neurology. 47: 1290-8. PMID 2123623 DOI: 10.1001/Archneur.1990.00530120034007  0.294
1975 Parkes JD, Tarsy D, Marsden CD, Bovill KT, Phipps JA, Rose P, Asselman P. Amphetamines in the treatment of Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 38: 232-7. PMID 1097600 DOI: 10.1136/jnnp.38.3.232  0.294
1980 Jenner P, Clow A, Reavill C, Theodorou A, Marsden CD. Stereoselective actions of substituted benzamide drugs on cerebral dopamine mechanisms Journal of Pharmacy and Pharmacology. 32: 39-44. PMID 6102125 DOI: 10.1111/J.2042-7158.1980.Tb12842.X  0.293
1993 Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine Movement Disorders. 8: 129-133. PMID 8097279 DOI: 10.1002/Mds.870080202  0.293
1986 Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease Movement Disorders : Official Journal of the Movement Disorder Society. 1: 85-87. PMID 3504235 DOI: 10.1002/Mds.870010112  0.293
1977 Pycock CJ, Marsden CD. Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease. Journal of the Neurological Sciences. 31: 113-21. PMID 833607 DOI: 10.1016/0022-510X(77)90009-0  0.293
2012 Debono AG, Marsden CD, Asselman P, Parkes JD. Bromocriptine and dopamine receptor stimulation. British Journal of Clinical Pharmacology. 3: 977-82. PMID 22216518 DOI: 10.1111/J.1365-2125.1976.TB00346.X  0.292
1980 Clow A, Theodorou A, Jenner P, Marsden CD. A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration Psychopharmacology. 69: 227-233. PMID 6774362 DOI: 10.1007/Bf00433087  0.292
1985 Rupniak NM, Hall MD, Kelly E, Fleminger S, Kilpatrick G, Jenner P, Marsden CD. Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs. Journal of Neural Transmission. 62: 249-66. PMID 2863324 DOI: 10.1007/Bf01252240  0.291
1987 Hong M, Jenner P, Marsden CD. Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats. Neuropharmacology. 26: 237-245. PMID 2884588 DOI: 10.1016/0028-3908(87)90214-0  0.29
1988 Jenner P, Boyce S, Marsden CD. Receptor changes during chronic dopaminergic stimulation. Journal of Neural Transmission-Supplement. 27: 161-175. PMID 2900291 DOI: 10.1007/978-3-7091-8954-2_14  0.289
1983 Reynolds LM, Dyer RG, Jenner P, Marsden CD. Hypophysectomy does not prevent increased cerebral dopamine turnover following sulpiride administration. The Journal of Pharmacy and Pharmacology. 35: 170-4. PMID 6132975 DOI: 10.1111/J.2042-7158.1983.Tb04299.X  0.289
1986 Quinn NP, Rossor MN, Marsden CD. Dementia And Parkinson'S Disease — Pathhological And Neurochemical Considerations British Medical Bulletin. 42: 86-90. PMID 3006860 DOI: 10.1093/Oxfordjournals.Bmb.A072104  0.288
1984 Hall MD, Cooper DR, Fleminger S, Rupniak NMJ, Jenner P, Marsden CD. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of l-DOPA to rats Neuropharmacology. 23: 545-553. PMID 6539859 DOI: 10.1016/0028-3908(84)90028-5  0.288
1988 Stewart B, Rose S, Jenner P, Marsden CD. Pilocarpine-induced purposeless chewing behaviour in rats is dependent on intact central stores of 5-HT. European Journal of Pharmacology. 142: 173-6. PMID 2961579 DOI: 10.1016/0014-2999(87)90671-6  0.285
1977 Bedard P, Parkes JD, Marsden CD. Nomifensine in Parkinson's disease. British Journal of Clinical Pharmacology. 187S-190S. PMID 334223 DOI: 10.1111/J.1365-2125.1977.TB05751.X  0.285
1983 Rupniak N, Hong M, Mansfield S, Fleminger S, Dyer R, Jenner P, Marsden CD. Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity. European Journal of Pharmacology. 93: 195-200. PMID 6139285 DOI: 10.1016/0014-2999(83)90137-1  0.285
1985 Boyce S, Kelly E, Davis A, Fleminger S, Jenner P, Marsden CD. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors. Biochemical Pharmacology. 34: 1665-9. PMID 2988552 DOI: 10.1016/0006-2952(85)90632-X  0.285
1989 Ueki A, Chong P, Albanese A, Rose S, Chivers J, Jenner P, Marsden C. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology. 28: 1089-1097. PMID 2510050 DOI: 10.1016/0028-3908(89)90122-6  0.284
1987 Jenner P, Marsden CD. Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacology. 26: 931-40. PMID 2889159 DOI: 10.1016/0028-3908(87)90072-4  0.284
1983 Hall MD, Jenner P, Marsden CD. Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration. Biochemical Pharmacology. 32: 2973-7. PMID 6626267 DOI: 10.1016/0006-2952(83)90405-7  0.284
1989 Nomoto M, Stahl S, Jenner P, Marsden CD. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 2: 37-45. PMID 2904119 DOI: 10.1002/Mds.870020105  0.283
1980 Reavill C, Leigh N, Jenner P, Marsden CD. Dopamine-mediated circling behaviour does not involve the nigro-tectal pathway. Experimental Brain Research. 37: 309-16. PMID 315328 DOI: 10.1007/Bf00237716  0.283
1977 Parkes JD, Debono AG, Marsden CD. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. Journal of Neurology, Neurosurgery, and Psychiatry. 39: 1101-8. PMID 1036999 DOI: 10.1136/jnnp.39.11.1101  0.281
1992 Rupniak NM, Boyce S, Steventon MJ, Iversen SD, Marsden CD. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Annals of Neurology. 32: 103-5. PMID 1642462 DOI: 10.1002/ana.410320118  0.281
1990 Raisman-Vozari R, Girault JA, Moussaoui S, Feuerstein C, Jenner P, Marsden CD, Agid Y. Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man. Brain Research. 507: 45-50. PMID 2105823 DOI: 10.1016/0006-8993(90)90520-L  0.281
1981 Kolbe H, Clow A, Jenner P, Marsden CD. Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors. Neurology. 31: 434-9. PMID 6111766 DOI: 10.1212/Wnl.31.4.434  0.279
1995 Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour. Biochemical Pharmacology. 49: 1185-93. PMID 7763300 DOI: 10.1016/0006-2952(95)00035-X  0.278
1991 Blunt S, Jenner P, Marsden CD. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts. Neuroscience. 40: 453-464. PMID 1902916 DOI: 10.1016/0306-4522(91)90133-9  0.276
1983 Rupniak NMJ, Jenner P, Marsden CD. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Life Sciences. 32: 2289-2311. PMID 6133203 DOI: 10.1016/0024-3205(83)90759-2  0.275
1983 Jenner P, Kerwin R, Rupniak NMJ, Murugaiah K, Hall MD, Fleminger S, Marsden CD. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. Journal of Neural Transmission-Supplement. 18: 205-212. DOI: 10.1007/978-3-7091-4408-4_19  0.274
1999 Pearce RKB, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets Psychopharmacology. 142: 51-60. PMID 10102782 DOI: 10.1007/S002130050861  0.274
1997 Seaton TA, Jenner P, Marsden CD. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. Journal of Neural Transmission (Vienna, Austria : 1996). 103: 315-29. PMID 8739843 DOI: 10.1007/Bf01271243  0.273
1995 Silva MT, Rose S, Hindmarsh JG, Aislaitner G, Gorrod JW, Moore PK, Jenner P, Marsden CD. Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole. British Journal of Pharmacology. 114: 257-8. PMID 7533610 DOI: 10.1111/J.1476-5381.1995.Tb13219.X  0.273
1994 Rose S, Hindmarsh JG, Steiger MJ, Bhatt M, Quinn NP, Jenner P, Marsden CD. Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease. Clinical Neuropharmacology. 17: 260-9. PMID 9316671 DOI: 10.1097/00002826-199406000-00005  0.272
1982 Murugaiah K, Theodorou A, Mann S, Clow A, Jenner P, Marsden CD. Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum Nature. 296: 570-572. PMID 6122161 DOI: 10.1038/296570a0  0.272
1975 Pycock CJ, Donaldson IM, Marsden CD. Circling behaviour produced by unilateral lesions in the region of the locus coeruleus in rats. Brain Research. 97: 317-29. PMID 1175049 DOI: 10.1016/0006-8993(75)90453-9  0.272
1987 Hong M, Kilpatrick GJ, Jenner P, Marsden CD. Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat. Neuropharmacology. 26: 1061-9. PMID 2889161 DOI: 10.1016/0028-3908(87)90249-8  0.272
1997 Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 522-32. PMID 8866493 DOI: 10.1002/Mds.870110507  0.271
1985 Kelly E, Jenner P, Marsden CD. Lack of effect of intranigral administration of a dopamine analogue, (+/-)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(+/-)-3-PPP], on nigrostriatal dopamine neurones. Neuroscience Letters. 56: 57-62. PMID 4011049 DOI: 10.1016/0304-3940(85)90440-9  0.27
1986 Bradbury AJ, Costall B, Domeney AM, Testa B, Jenner PG, Marsden CD, Naylor RJ. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety. Neuroscience Letters. 61: 121-6. PMID 2417166 DOI: 10.1016/0304-3940(85)90411-2  0.27
1997 Toffa S, Kunikowska GM, Zeng BY, Jenner P, Marsden CD. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. Journal of Neural Transmission (Vienna, Austria : 1996). 104: 67-75. PMID 9085194 DOI: 10.1007/Bf01271295  0.269
1980 Clow A, Theodorou A, Jenner P, Marsden CD. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic European Journal of Pharmacology. 63: 135-144. PMID 6103813 DOI: 10.1016/0014-2999(80)90437-9  0.269
1986 Moser A, Reavill C, Jenner P, Marsden CD, Cramer H. Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat. Experimental Brain Research. 62: 567-71. PMID 2873048 DOI: 10.1007/Bf00236035  0.269
1992 Blunt SB, Jenner P, Marsden CD. Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa. Brain Research. 582: 299-311. PMID 1393551 DOI: 10.1016/0006-8993(92)90147-2  0.269
1978 Jenner P, Clow A, Reavill C, Theodorou A, Marsden CD. A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs Life Sciences. 23: 545-549. PMID 692279 DOI: 10.1016/0024-3205(78)90032-2  0.268
1975 Tarsy D, Parkes JD, Marsden CD. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. Journal of Neurology, Neurosurgery, and Psychiatry. 38: 331-5. PMID 1095689 DOI: 10.1136/jnnp.38.4.331  0.268
1981 Dyer RG, Murugaiah K, Theodorou A, Clow A, Jenner P, Marsden CD. During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated Life Sciences. 28: 167-174. PMID 6114373 DOI: 10.1016/0024-3205(81)90549-X  0.268
1985 Nomoto M, Jenner P, Marsden CD. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neuroscience Letters. 57: 37-41. PMID 3162113 DOI: 10.1016/0304-3940(85)90037-0  0.267
1983 Jenner P, Sheehy M, Marsden CD. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. British Journal of Clinical Pharmacology. 277S-289S. PMID 6337612 DOI: 10.1111/J.1365-2125.1983.TB05876.X  0.267
1995 Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate. Psychopharmacology. 117: 403-12. PMID 7604140 DOI: 10.1007/BF02246211  0.266
1986 Rupniak NM, Briggs RS, Petersen MM, Mann S, Reavill C, Jenner P, Marsden CD. Differential alterations in striatal acetylcholine function in rats during 12 months' continuous administration of haloperidol, sulpiride, or clozapine. Clinical Neuropharmacology. 9: 282-92. PMID 3719573 DOI: 10.1097/00002826-198606000-00006  0.265
1986 Davis AS, Jenner P, Marsden CD. A comparison of motor behaviours in groups of rats distinguished by their climbing response to apomorphine British Journal of Pharmacology. 87: 129-137. PMID 3955297 DOI: 10.1111/J.1476-5381.1986.Tb10164.X  0.265
1980 Jenner P, Leigh N, Marsden CD, Reavill C. Superior colliculus lesions do not alter dopamine mediated circling behaviour [proceedings]. British Journal of Pharmacology. 66: 479P-480P. PMID 575063  0.265
1996 McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochemical Pharmacology. 52: 29-34. PMID 8678905 DOI: 10.1016/0006-2952(96)00133-5  0.264
1989 Chivers JK, Reavill C, Jenner P, Marsden CD. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation. The Journal of Pharmacy and Pharmacology. 40: 613-9. PMID 2907027 DOI: 10.1111/J.2042-7158.1988.Tb05320.X  0.263
1986 Bradbury AJ, Costall B, Domeney AM, Jenner PJ, Marsden CD, Naylor RJ. The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra. Neuroscience Letters. 67: 208-12. PMID 2425303 DOI: 10.1016/0304-3940(86)90399-X  0.263
1979 Clow A, Jenner P, Theodorou A, Marsden CD. Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months [15] Nature. 278: 59-61. PMID 570253 DOI: 10.1038/278059A0  0.262
1987 Weller ME, Rose S, Jenner P, Marsden CD. In vitro characterisation of dopamine receptors in the superior colliculus of the rat. Neuropharmacology. 26: 347-54. PMID 2438586 DOI: 10.1016/0028-3908(87)90187-0  0.262
1977 Hallett M, Chadwick D, Marsden CD. Ballistic movement overflow myoclonus a form of essential myoclonus. Brain : a Journal of Neurology. 100: 299-312. PMID 884486 DOI: 10.1093/Brain/100.2.299  0.262
1996 Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Movement Disorders : Official Journal of the Movement Disorder Society. 10: 731-40. PMID 8749992 DOI: 10.1002/Mds.870100606  0.262
1991 Blunt SB, Jenner P, Marsden CD. The effect ofl-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography Neuroscience. 43: 95-110. PMID 1681462 DOI: 10.1016/0306-4522(91)90420-S  0.261
1997 Granata R, Wenning GK, Jolkkonen J, Jenner P, Marsden CD. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. Journal of Neural Transmission (Vienna, Austria : 1996). 103: 249-60. PMID 8739837 DOI: 10.1007/Bf01271237  0.26
1979 Clow A, Jenner P, Marsden CD. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. European Journal of Pharmacology. 57: 365-75. PMID 39769 DOI: 10.1016/0014-2999(79)90499-0  0.26
1987 Rupniak NM, Prestwich SA, Horton RW, Jenner P, Marsden CD. Alterations in cerebral glutamic acid decarboxylase and 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine. Journal of Neural Transmission. 68: 113-25. PMID 3806083 DOI: 10.1007/Bf01244643  0.26
1992 Thomas KL, Rose S, Jenner P, Marsden CD. Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum Biochemical Pharmacology. 44: 83-91. PMID 1321631 DOI: 10.1016/0006-2952(92)90041-G  0.259
1977 Elliott PN, Huizing G, Jenner P, Marsden CD, Miller R. Substituted benzamides as dopamine antagonists [proceedings]. British Journal of Pharmacology. 57: 472P. PMID 974363  0.258
1986 Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography Journal of Neurology, Neurosurgery and Psychiatry. 49: 853-860. PMID 3091770 DOI: 10.1136/Jnnp.49.8.853  0.258
1991 Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jähnig P, Honoré T, Turski L, Wachtel H, Jenner P, Marsden CD. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 3: 203-13. PMID 1835581 DOI: 10.1007/BF02259538  0.257
1990 Rose S, Nomoto M, Jackson EA, Gibb WR, Jenner P, Marsden CD. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset. European Journal of Pharmacology. 181: 97-103. PMID 2117541 DOI: 10.1016/0014-2999(90)90249-6  0.256
1987 Marsden CD, Jenner PG. The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Ciba Foundation Symposium. 126: 239-56. PMID 3556086 DOI: 10.1002/9780470513422.ch15  0.256
1990 Coleman RJ, Quinn NP, Traub M, Marsden CD. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 53: 102-5. PMID 1968963 DOI: 10.1136/jnnp.53.2.102  0.255
1989 Jackson EA, Jenner P, Marsden CD. Behavioural and morphological changes following treatment with GM-1 ganglioside of rats with an electrolytic lesion of the substantia nigra. Neuropharmacology. 28: 543-55. PMID 2569173 DOI: 10.1016/0028-3908(89)90132-9  0.255
2013 Thongsaard W, Marsden C. Effect of Thunbergia laurifolia extract on extracellular dopamine level in rat nucleus accumbens. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet. S85-9. PMID 23724461  0.255
1990 Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (New York, N.Y.). 247: 574-7. PMID 2105529 DOI: 10.1126/science.2105529  0.255
1988 Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain : a Journal of Neurology. 299-321. PMID 3378138 DOI: 10.1093/BRAIN/111.2.299  0.255
1989 Chivers JK, Reavill C, Jenner P, Marsden CD. Definition of the in-vivo binding of [3H]spiperone in rat brain using substituted benzamide drugs. The Journal of Pharmacy and Pharmacology. 41: 106-11. PMID 2568417 DOI: 10.1111/J.2042-7158.1989.Tb06403.X  0.255
1985 Kelly E, Jenner P, Marsden CD. Evidence that [3H]dopamine is taken up and released from nondopaminergic nerve terminals in the rat substantia nigra in vitro. Journal of Neurochemistry. 45: 137-44. PMID 3923157 DOI: 10.1111/J.1471-4159.1985.Tb05485.X  0.254
1995 Gnanalingham KK, Smith LA, Jenner P, Erol DD, Hunter AJ, Marsden CD. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset Psychopharmacology. 117: 275-286. PMID 7770603 DOI: 10.1007/Bf02246102  0.253
1976 Chadwick D, Reynolds EH, Marsden CD. Anticonvulsant-induced dyskinesias: A comparison with dyskinesias induced by neuroleptics Journal of Neurology, Neurosurgery and Psychiatry. 39: 1210-1218. PMID 1011032 DOI: 10.1136/jnnp.39.12.1210  0.253
1990 Blunt SB, Jenner P, Marsden CD. Chapter 56 The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats Progress in Brain Research. 82: 493-498. PMID 2127116 DOI: 10.1016/S0079-6123(08)62639-4  0.252
1987 Dick JP, Cantello R, Buruma O, Gioux M, Benecke R, Day BL, Rothwell JC, Thompson PD, Marsden CD. The Bereitschaftspotential, L-DOPA and Parkinson's disease. Electroencephalography and Clinical Neurophysiology. 66: 263-74. PMID 2434310 DOI: 10.1016/0013-4694(87)90075-7  0.252
1986 Bradbury AJ, Costall B, Jenner PG, Kelly ME, Marsden CD, Naylor RJ. MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area. Neuropharmacology. 25: 939-41. PMID 3774119 DOI: 10.1016/0028-3908(86)90025-0  0.251
1984 Murugaiah K, Fleminger S, Hall MD, Theodorou A, Jenner P, Marsden CD. Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats Neuropharmacology. 23: 599-609. PMID 6540376 DOI: 10.1016/0028-3908(84)90139-4  0.25
1976 Parkes JD, Marsden CD, Donaldson I, Galea-Debono A, Walters J, Kennedy G, Asselman P. Bromocriptine treatment in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 39: 184-93. PMID 772175 DOI: 10.1136/jnnp.39.2.184  0.25
1986 Garvey J, Petersen M, Waters CM, Rose SP, Hunt S, Briggs R, Jenner P, Marsden CD. Administration of MPTP to the common marmoset does not alter cortical cholinergic function. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 129-34. PMID 3143064 DOI: 10.1002/Mds.870010207  0.25
1998 Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs. 55: 17-22. PMID 9483166  0.249
1978 Clow A, Jenner P, Marsden CD. An experimental model of tardive dyskinesias. Life Sciences. 23: 421-3. PMID 567729 DOI: 10.1016/0024-3205(78)90146-7  0.249
1980 Jenner P, Leigh N, Marsden CD, Reavill C. Dopamine mediated circling behaviour is modulated by lesions of the ventromedial nucleus of the thalamus [proceedings]. British Journal of Pharmacology. 67: 432P. PMID 574044  0.249
1975 Tarsy D, Parkes JD, Marsden CD. Clonidine in Parkinson disease. Archives of Neurology. 32: 134-6. PMID 1122178 DOI: 10.1001/ARCHNEUR.1975.00490440084016  0.248
1997 McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration : a Journal For Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration. 5: 265-74. PMID 8910905 DOI: 10.1006/Neur.1996.0035  0.248
1995 Jolkkonen J, Granata R, Jenner P, Marsden CD. Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum Neuropeptides. 29: 109-114. PMID 7477761 DOI: 10.1016/0143-4179(95)90093-4  0.248
1987 Chivers J, Jenner P, Marsden CD. Pharmacological characterization of binding sites identified in rat brain following in vivo administration of [3H]-spiperone. British Journal of Pharmacology. 90: 467-78. PMID 2882801 DOI: 10.1111/J.1476-5381.1987.Tb11196.X  0.248
1992 Thomas KL, Rose S, Jenner P, Marsden CD. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation Biochemical Pharmacology. 44: 73-82. PMID 1321630 DOI: 10.1016/0006-2952(92)90040-P  0.247
1991 Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RS. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain : a Journal of Neurology. 1539-52. PMID 2123119 DOI: 10.1093/Brain/113.5.1539  0.246
1980 Clow A, Theodorou A, Jenner P, Marsden CD. Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal Advances in Biochemical Psychopharmacology. 24: 335-340. PMID 7190762  0.245
1975 Pycock C, Tarsy D, Marsden CD. Inhibition of circling behavior by neuroleptic drugs in mice with unilateral 6-hydroxydopamine lesions of the striatum. Psychopharmacologia. 45: 211-9. PMID 1240638 DOI: 10.1007/BF00429063  0.244
1983 Jenner P, Kerwin R, Rupniak NM, Murugaiah K, Hall MD, Fleminger S, Marsden CD. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. Journal of Neural Transmission. Supplementum. 18: 205-12. PMID 6135741  0.244
1975 Jenner P, Marsden CD, Peringer E. Proceedings: Behavioural and biochemical evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. British Journal of Pharmacology. 54: 275P-276P. PMID 1148554  0.244
1983 Fleminger S, Rupniak NM, Hall MD, Jenner P, Marsden CD. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. Biochemical Pharmacology. 32: 2921-7. PMID 6138043 DOI: 10.1016/0006-2952(83)90397-0  0.244
1984 Luscombe G, Jenner P, Marsden CD. Correlation of [3H]5-hydroxytryptamine (5HT) binding to brain stem preparations and the production and prevention of myoclonus in guinea pig by 5HT agonists and antagonists European Journal of Pharmacology. 104: 235-244. PMID 6499922 DOI: 10.1016/0014-2999(84)90398-4  0.243
1989 Temlett JA, Quinn NP, Marsden CD, Lataste X, Jaton AL. The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist. Clinical Neuropharmacology. 12: 55-9. PMID 2565766 DOI: 10.1097/00002826-198902000-00007  0.243
1991 Taylor MD, de Ceballos ML, Rose S, Chong PN, Jenner P, Marsden CD. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP. Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 3: 99-108. PMID 1716907 DOI: 10.1007/BF02260885  0.241
1988 Lindvall O, Rehncrona S, Gustavii B, Brundin P, Astedt B, Widner H, Lindholm T, Björklund A, Leenders KL, Rothwell JC, Frackowiak R, Marsden CD, Johnels B, Steg G, Freedman R, et al. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet. 2: 1483-4. PMID 2904587 DOI: 10.1016/S0140-6736(88)90950-6  0.241
1988 Taquet H, Nomoto M, Rose S, Jenner P, Javoy-Agid F, Mauborgne A, Benoliel JJ, Marsden CD, Legrand JC, Agid Y, Hamon M, Cesselin F. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment. Neuropeptides. 12: 105-110. PMID 2468106 DOI: 10.1016/0143-4179(88)90039-X  0.24
1982 Murugaiah K, Mann S, Theodorou AE, Jenner P, Marsden CD. Increased striatal acetylcholine after 14 months cis-flupenthixol treatment in rats suggests functional supersensitivity of dopamine receptors Life Sciences. 31: 181-188. PMID 6889662 DOI: 10.1016/0024-3205(82)90431-3  0.24
1985 Jenner P, Rupniak NM, Marsden CD. Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats. Psychopharmacology. Supplementum. 2: 174-81. PMID 3159009 DOI: 10.1007/978-3-642-70140-5_21  0.24
1986 Lu C, Thompson PD, Quinn NP, Parkes JD, Marsden CD. Ramsay Hunt syndrome and coeliac disease: a new association? Movement Disorders. 1: 209-219. PMID 3504245 DOI: 10.1002/Mds.870010306  0.24
1986 Kilpatrick GJ, el Tayar N, Van de Waterbeemd H, Jenner P, Testa B, Marsden CD. The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors. Molecular Pharmacology. 30: 226-34. PMID 2943980  0.24
1988 Critchley PH, Grandas Perez F, Quinn NP, Parkes JD, Marsden CD. Continuous subcutaneous lisuride infusions in Parkinson's disease. Journal of Neural Transmission. Supplementum. 27: 55-60. PMID 2969953 DOI: 10.1007/978-3-7091-8954-2_6  0.239
2007 Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain Neuropharmacology. 52: 405-414. PMID 17020775 DOI: 10.1016/j.neuropharm.2006.07.035  0.238
1993 Rose S, Nomoto M, Jackson EA, Gibb WR, Jaehnig P, Jenner P, Marsden CD. Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. European Journal of Pharmacology. 230: 177-85. PMID 8422900 DOI: 10.1016/0014-2999(93)90800-W  0.238
1977 Castall B, Marsden CD, Naylor RJ, Pycock CJ. Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei. Brain Research. 123: 89-111. PMID 300267 DOI: 10.1016/0006-8993(77)90645-X  0.237
1996 Hurley MJ, Jolkkonen J, Stubbs CM, Jenner P, Marsden CD. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Research. 709: 259-64. PMID 8833762 DOI: 10.1016/0006-8993(95)01309-1  0.237
1979 Clow A, Jenner P, Marsden CD. Supersensitivity of cerebral dopamine receptors during on-going chronic (six months) administration of trifluoperazine to rats [proceedings]. British Journal of Pharmacology. 64: 414P. PMID 719266  0.237
1997 Barbato L, Stocchi F, Monge A, Vacca L, Ruggieri S, Nordera G, Marsden CD. The long-duration action of levodopa may be due to a postsynaptic effect. Clinical Neuropharmacology. 20: 394-401. PMID 9331515 DOI: 10.1097/00002826-199710000-00003  0.237
1979 Clow A, Jenner P, Marsden CD, Reavill C, Theodorou A. Stereoselective blockade of cerebral dopamine receptors by sulpiride and sultopride British Journal of Pharmacology. 67. PMID 497556  0.236
1995 Playford ED, Britton TC, Thompson PD, Brooks DJ, Findley LJ, Marsden CD. Exacerbation of postural tremor with emergence of parkinsonism after treatment with neuroleptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry. 58: 487-489. PMID 7738563 DOI: 10.1136/Jnnp.58.4.487  0.236
1993 Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse (New York, N.Y.). 14: 184-94. PMID 8332947 DOI: 10.1002/Syn.890140212  0.236
1986 Bradbury AJ, Costall B, Jenner PG, Kelly ME, Marsden CD, Naylor RJ. The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice. Antagonism by monoamine oxidase inhibitors. Neuropharmacology. 25: 897-904. PMID 3022182 DOI: 10.1016/0028-3908(86)90016-X  0.236
1997 Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. Journal of Neurology. 243: 68-72. PMID 8869390 DOI: 10.1007/BF00878534  0.236
1984 Luscombe G, Jenner P, Marsden CD. 5-Hydroxytryptamine (5-HT)-dependent myoclonus in guinea pigs is induced through brainstem 5-HT-1 receptors. Neuroscience Letters. 44: 241-6. PMID 6728293 DOI: 10.1016/0304-3940(84)90029-6  0.235
1986 Gibb WR, Lees AJ, Jenner P, Marsden CD. The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset. Neuroscience Letters. 65: 79-83. PMID 3486388 DOI: 10.1016/0304-3940(86)90123-0  0.235
1997 Steiger MJ, Thompson PD, Marsden CD. Disordered axial movement in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 61: 645-8. PMID 8971118 DOI: 10.1136/jnnp.61.6.645  0.235
1979 Jenner P, Marsden CD. Tardive dyskinesias. Lancet (London, England). 2: 900. PMID 90986 DOI: 10.1016/S0140-6736(79)92708-9  0.234
1978 Price PA, Parkes JD, Marsden CD. Sodium valproate in the treatment of levodopa-induced dyskinesia. Journal of Neurology, Neurosurgery, and Psychiatry. 41: 702-6. PMID 355601 DOI: 10.1136/jnnp.41.8.702  0.234
1979 Jenner P, Marsden CD. The substituted benzamides--a novel class of dopamine antagonists. Life Sciences. 25: 479-485. PMID 40086 DOI: 10.1016/0024-3205(79)90559-9  0.233
1975 Gledhill R, Lewis P, Marsden CD, Rake M. Is Mollaret'S Meningitis Another Periodic Disorder Responsive To Colchicine ? The Lancet. 306: 415-415. PMID 51225 DOI: 10.1016/S0140-6736(75)92936-0  0.232
1988 Cooper DR, Marrel C, van de Waterbeemd H, Testa B, Jenner P, Marsden CD. L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice. The Journal of Pharmacy and Pharmacology. 39: 809-18. PMID 2891818 DOI: 10.1111/J.2042-7158.1987.Tb05123.X  0.232
1982 Jenner P, Marsden CD. The mode of action of sulpiride as an atypical antidepressant agent. Advances in Biochemical Psychopharmacology. 32: 85-103. PMID 7046370  0.232
1985 Murugaiah K, Theodorou A, Clow A, Jenner P, Marsden CD. Effects of discontinuous drug administration on the development of dopamine receptor supersensitivity during chronic trifluoperazine or cis-flupenthixol administration to rats Psychopharmacology. 86: 228-232. PMID 3927361 DOI: 10.1007/BF00431715  0.232
1977 Jenner P, Marsden CD, Pycock CJ. Chronic amphetamine administration and central dopamine receptor sensitivity [proceedings]. British Journal of Pharmacology. 61: 142P. PMID 912190  0.231
1983 Murugaiah K, Theodorou A, Jenner P, Marsden CD. Alterations in cerebral dopamine function caused by administration of cis- or trans-flupenthixol for up to 18 months Neuroscience. 10: 811-819. PMID 6685826 DOI: 10.1016/0306-4522(83)90218-X  0.23
1978 Elliott PNC, Jenner P, Marsden CD. Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs. Journal of Pharmacy and Pharmacology. 30: 788-791. PMID 32246 DOI: 10.1111/J.2042-7158.1978.Tb13394.X  0.229
1988 Albanese A, Jenner P, Marsden CD, Stephenson JD. Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience Letters. 87: 46-50. PMID 3132651 DOI: 10.1016/0304-3940(88)90143-7  0.229
1988 Harrington RC, Wieck A, Marks IM, Marsden CD. Writer's cramp: not associated with anxiety. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 195-200. PMID 3193960 DOI: 10.1002/Mds.870030303  0.228
1976 Donaldson IM, Jenner P, Marsden CD. Is metoclopramide a directly acting dopamine receptor antagonist? British Journal of Pharmacology. 56: 373P. PMID 1260201  0.228
1992 Taylor MD, De Ceballos ML, Rose S, Jenner P, Marsden CD. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. European Journal of Pharmacology. 219: 183-92. PMID 1385171 DOI: 10.1016/0014-2999(92)90295-F  0.227
1976 Debono AG, Donaldson I, Marsden CD, Parkes JD. Letter: Bromocriptine in parkinsonism. Lancet (London, England). 2: 987-8. PMID 53479  0.227
1984 Hall MD, Jenner P, Kelly E, Marsden CD. Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat. British Journal of Pharmacology. 79: 599-610. PMID 6418246 DOI: 10.1111/J.1476-5381.1983.Tb11035.X  0.226
1976 Peringer E, Jenner P, Donaldson IM, Marsden CD, Miller R. Metoclopramide and dopamine receptor blockade Neuropharmacology. 15: 463-469. DOI: 10.1016/0028-3908(76)90056-3  0.225
2000 Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Medical Journal. 41: 167-84. PMID 10817016 DOI: 10.3349/ymj.2000.41.2.167  0.225
1987 Waters CM, Hunt SP, Jenner P, Marsden CD. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience. 23: 1025-39. PMID 2893993 DOI: 10.1016/0306-4522(87)90178-3  0.225
1992 Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Annals of Neurology. 31: 184-92. PMID 1575457 DOI: 10.1002/Ana.410310209  0.225
1989 Nomoto M, Jenner P, Marsden CD. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset. Neuroscience Letters. 93: 275-80. PMID 2907373 DOI: 10.1016/0304-3940(88)90095-X  0.225
1980 Jenner P, Marsden CD, Thanki CM. Behavioural Changes Induced By N,N‐Dimethyltryptamine In Rodents British Journal of Pharmacology. 69: 69-80. PMID 6769527 DOI: 10.1111/J.1476-5381.1980.Tb10884.X  0.225
1986 Bradbury AJ, Costall B, Domeney AM, Jenner P, Kelly ME, Marsden CD, Naylor RJ. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature. 319: 56-7. PMID 3484542 DOI: 10.1038/319056A0  0.224
1974 Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 37: 422-6. PMID 4838913 DOI: 10.1136/jnnp.37.4.422  0.224
1984 Cooper DR, Marrel C, Testa B, van de Waterbeemd H, Quinn N, Jenner P, Marsden CD. L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clinical Neuropharmacology. 7: 89-98. PMID 6704979 DOI: 10.1097/00002826-198403000-00005  0.223
1986 Jenner P, Taquet H, Mauborgne A, Benoliel JT, Cesselin F, Rose S, Javoy-Agid F, Agid Y, Marsden CD. Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset. Journal of Neurochemistry. 47: 1548-51. PMID 2428937 DOI: 10.1111/J.1471-4159.1986.Tb00793.X  0.223
1991 Sawle GV, Leenders KL, Brooks DJ, Harwood G, Lees AJ, Frackowiak RS, Marsden CD. Dopa-responsive dystonia: [18F]dopa positron emission tomography. Annals of Neurology. 30: 24-30. PMID 1681782 DOI: 10.1002/Ana.410300106  0.223
1995 Collins P, Broekkamp CL, Jenner P, Marsden CD. Electromyographical differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat. Psychopharmacology. 112: 428-36. PMID 7871053 DOI: 10.1007/Bf02244890  0.223
1973 Marsden CD, Barry PE, Parkes JD, Zilkha KJ. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. Journal of Neurology, Neurosurgery, and Psychiatry. 36: 10-4. PMID 4691682 DOI: 10.1136/jnnp.36.1.10  0.223
1995 Gnanalingham KK, Milkowski NA, Smith LA, Hunter AJ, Jenner P, Marsden CD. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset European Journal of Pharmacology. 277: 235-241. PMID 7493614 DOI: 10.1016/0014-2999(95)00086-Z  0.223
1981 Reavill C, Jenner P, Leigh N, Marsden CD. The role of nigral projections to the thalamus in drug-induced circling behaviour in the rat. Life Sciences. 28: 1457-66. PMID 7017327 DOI: 10.1016/0024-3205(81)90377-5  0.223
1989 Löschmann PA, Chong PN, Nomoto M, Tepper PG, Horn AS, Jenner P, Marsden CD. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437 European Journal of Pharmacology. 166: 373-380. PMID 2572426 DOI: 10.1016/0014-2999(89)90348-8  0.222
1981 Schachter M, Sheehy MP, Parkes JD, Marsden CD. Lisuride in the treatment of Parkinsonism. Acta Neurologica Scandinavica. 62: 382-5. PMID 7468157 DOI: 10.1111/j.1600-0404.1980.tb03050.x  0.222
1994 Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Annals of Neurology. 36: 348-355. PMID 8080242 DOI: 10.1002/Ana.410360305  0.221
1981 Schachter M, Marsden CD, Parkes JD, Jenner P, Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. Journal of Neurology, Neurosurgery, and Psychiatry. 43: 1016-21. PMID 6777463 DOI: 10.1136/jnnp.43.11.1016  0.221
1984 Marsden CD. Function of the basal ganglia as revealed by cognitive and motor disorders in Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 11: 129-35. PMID 6713311 DOI: 10.1017/S031716710004628X  0.221
1991 Taylor MD, de Ceballos ML, Jenner P, Marsden CD. Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat. Biochemical Pharmacology. 41: 1385-91. PMID 1673340 DOI: 10.1016/0006-2952(91)90112-I  0.221
1997 Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Björklund A, Brooks DJ, Marsden CD, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology. 42: 95-107. PMID 9225690 DOI: 10.1002/Ana.410420115  0.221
1986 De Ceballos ML, Jenner P, Marsden CD. Acute and repeated administration of sulpiride alters Met-and Leu-enkephalin content of rat brain. Neuroscience Letters. 68: 322-6. PMID 3748458 DOI: 10.1016/0304-3940(86)90510-0  0.221
1984 Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa Neurology. 34: 1131-1136. PMID 6540399 DOI: 10.1212/WNL.34.9.1131  0.221
1994 Fernandez A, de Ceballos ML, Jenner P, Marsden CD. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience. 61: 73-9. PMID 7969897 DOI: 10.1016/0306-4522(94)90061-2  0.22
1987 Gibb C, Willoughby J, Glover V, Sandler M, Testa B, Jenner P, Marsden CD. Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary Neuroscience Letters. 76: 316-322. PMID 3495757 DOI: 10.1016/0304-3940(87)90422-8  0.22
1982 Reavill C, Leigh N, Jenner P, Marsden CD. Critical role of midbrain reticular formation in the expression of dopamine-mediated circling behaviour. Advances in Biochemical Psychopharmacology. 30: 187-204. PMID 6800220  0.22
1976 Costall B, Naylor RJ, Marsden CD, Pycock CJ. Serotoninergic modulation of the dopamine response from the nucleus accumbens. The Journal of Pharmacy and Pharmacology. 28: 523-6. PMID 7657  0.219
1975 Peringer E, Jenner P, Marsden CD. Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5-hydroxytryptamine. The Journal of Pharmacy and Pharmacology. 27: 442-4. PMID 237096 DOI: 10.1111/J.2042-7158.1975.Tb09477.X  0.219
1996 Pearce RKB, Collins P, Jenner P, Emmett C, Marsden CD. Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset Synapse. 23: 192-200. PMID 8807747 DOI: 10.1002/(Sici)1098-2396(199607)23:3<192::Aid-Syn8>3.0.Co;2-3  0.218
1974 Horrocks PM, Vicary DJ, Rees JE, Parkes JD, Marsden CD. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 36: 936-41. PMID 4772727 DOI: 10.1136/jnnp.36.6.936  0.218
1996 Hurley MJ, Stubbs CM, Jenner P, Marsden CD. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neuroscience Letters. 214: 75-8. PMID 8878087 DOI: 10.1016/0304-3940(96)12884-6  0.218
1996 Owen AD, Schapira AHV, Jenner P, Marsden CD. Oxidative stress and Parkinson's disease Annals of the New York Academy of Sciences. 786: 217-223. PMID 8687021 DOI: 10.1111/J.1749-6632.1996.Tb39064.X  0.218
1981 Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A. Lisuride in parkinsonism. Annals of Neurology. 9: 48-52. PMID 7212665 DOI: 10.1002/ANA.410090109  0.218
1985 Bradbury AJ, Costall B, Jenner PG, Kelly ME, Marsden CD, Naylor RJ. The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment. Neuroscience Letters. 58: 177-81. PMID 2413398 DOI: 10.1016/0304-3940(85)90160-0  0.218
1978 Marsden CD, Parkes JD. Bromocriptine in parkinsonism. Lancet (London, England). 2: 419-20. PMID 73879 DOI: 10.1016/S0140-6736(76)92436-3  0.217
1975 Galea Debono A, Donaldson I, Marsden C, Parkes J. BROMOCRIPTINE IN PARKINSONISM The Lancet. 306: 987-988. DOI: 10.1016/S0140-6736(75)90413-4  0.217
1989 Stewart BR, Jenner P, Marsden CD. The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat. Psychopharmacology. 96: 55-62. PMID 2906443 DOI: 10.1007/BF02431533  0.217
1994 Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. An autoradiographic study of the differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on striatal and extrastriatal D-1 and D-2 dopamine receptors in the rat. Neuropharmacology. 33: 647-55. PMID 7936100 DOI: 10.1016/0028-3908(94)90170-8  0.216
1982 Quinn N, Marsden CD, Parkes JD. COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA The Lancet. 320: 412-415. PMID 6124807 DOI: 10.1016/S0140-6736(82)90442-1  0.216
1992 Marsden C. Dopamine and basal ganglia disorders in humans Seminars in Neuroscience. 4: 171-178. DOI: 10.1016/1044-5765(92)90015-T  0.215
1982 Rupniak NM, Jenner P, Marsden CD. The absence of sodium ions does not explain the failure of sulpiride to inhibit, in vitro, rat striatal dopamine-sensitive adenylate cyclase. The Journal of Pharmacy and Pharmacology. 33: 602-3. PMID 6117643 DOI: 10.1111/J.2042-7158.1981.Tb13877.X  0.214
1994 de Ceballos ML, Fernandez A, Jenner P, Marsden CD. Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients. Neuroscience Letters. 160: 163-6. PMID 7504224 DOI: 10.1016/0304-3940(93)90404-9  0.214
1998 McNaught KSP, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease Biochemical Pharmacology. 56: 921-933. PMID 9776302 DOI: 10.1016/S0006-2952(98)00142-7  0.214
1989 Leenders KL, Frackowiak RS, Quinn N, Brooks D, Sumner D, Marsden CD. Ipsilateral blepharospasm and contralateral hemidystonia and parkinsonism in a patient with a unilateral rostral brainstem-thalamic lesion: structural and functional abnormalities studied with CT, MRI, and PET scanning. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 51-8. PMID 2973558 DOI: 10.1002/Mds.870010107  0.212
1980 Clow A, Jenner P, Marsden CD, Theodorou A. Regional changes in brain dopamine receptor function during six months trifluoperazine administration to rats British Journal of Pharmacology. 68. PMID 7357176  0.212
1981 Marsden CD. Dopamine hypothesis in acute psychosis. The British Journal of Psychiatry : the Journal of Mental Science. 138: 269-70. PMID 7272624 DOI: 10.1192/BJP.138.3.269  0.212
1976 Parkes JD, Bedard P, Marsden CD. Letter: Chorea and torsion in parkinsonism. Lancet (London, England). 2: 155. PMID 59231 DOI: 10.1016/s0140-6736(76)92894-4  0.211
1984 Dewar D, Jenner P, Marsden CD. Lesions of the globus pallidus, entopeduncular nucleus and substantia nigra alter dopamine mediated circling behaviour. Experimental Brain Research. 52: 281-92. PMID 6641888 DOI: 10.1007/Bf00236638  0.211
1995 Jolkkonen J, Jenner P, Marsden CD. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Molecular Brain Research. 32: 297-307. PMID 7500841 DOI: 10.1016/0169-328X(95)00084-6  0.211
1996 Fernandez A, De Ceballos ML, Rose S, Jenner P, Marsden CD. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease Brain. 119: 823-830. PMID 8673494 DOI: 10.1093/Brain/119.3.823  0.21
1978 Jenner P, Elliott PN, Clow A, Reavill C, Marsden CD. A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs. The Journal of Pharmacy and Pharmacology. 30: 46-8. PMID 22724 DOI: 10.1111/J.2042-7158.1978.Tb13151.X  0.209
1986 Fitzmaurice H, Fowler CJ, Rickards D, Kirby RS, Quinn NP, Marsden CD, Milroy EJ, Turner-Warwick RT. Micturition disturbance in Parkinson's disease. British Journal of Urology. 57: 652-6. PMID 4084724 DOI: 10.1111/J.1464-410X.1985.TB07025.X  0.209
1981 Theodorou A, Gommeren W, Clow A, Leysen J, Jenner P, Marsden CD. Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain Life Sciences. 28: 1621-1627. PMID 7242249 DOI: 10.1016/0024-3205(81)90317-9  0.209
1989 de Ceballos ML, Baker M, Rose S, Jenner P, Marsden CD. Do enkephalins in basal ganglia mediate a physiological motor rest mechanism? Movement Disorders : Official Journal of the Movement Disorder Society. 1: 223-33. PMID 3504246 DOI: 10.1002/Mds.870010402  0.208
1984 Jenner P, Marsden CD. Multiple dopamine receptors in brain and the pharmacological action of substituted benzamide drugs. Acta Psychiatrica Scandinavica. Supplementum. 311: 109-23. PMID 6142587 DOI: 10.1111/j.1600-0447.1984.tb06863.x  0.208
1996 Zeng B‐, Jenner P, Marsden CD. Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachykinin mRNA by foetal dopamine cells in unilateral 6-hydroxydopamine-lesioned rat striatum parallels functional recovery. Movement Disorders. 11: 43-52. PMID 8771066 DOI: 10.1002/Mds.870110109  0.207
1984 Dick JP, Cowan JM, Day BL, Berardelli A, Kachi T, Rothwell JC, Marsden CD. The corticomotoneurone connection is normal in Parkinson's disease. Nature. 310: 407-9. PMID 6462225 DOI: 10.1038/310407A0  0.207
1994 Lindvall O, Sawle G, Widner H, Rothwell JC, Björklund A, Brooks D, Brundin P, Frackowiak R, Marsden CD, Odin P. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Annals of Neurology. 35: 172-80. PMID 8109898 DOI: 10.1002/ana.410350208  0.205
1995 Cooper JM, Daniel SE, Marsden CD, Schapira AH. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Movement Disorders : Official Journal of the Movement Disorder Society. 10: 295-7. PMID 7651446 DOI: 10.1002/MDS.870100311  0.205
1988 Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychological Medicine. 17: 899-904. PMID 3432464 DOI: 10.1017/S0033291700000702  0.205
1991 Widner H, Brundin P, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD, Björklund A. Transplanted allogeneic fetal dopamine neurons survive and improve motor function in idiopathic Parkinson's disease. Transplantation Proceedings. 23: 793-5. PMID 1990693  0.205
1986 Kilpatrick GJ, Jenner P, Marsden CD. [125I]Spiperone is not a useful ligand for studying the CHAPS solubilized dopamine D-2 receptor from rat striatum. Journal of Pharmacy and Pharmacology. 38: 406-408. PMID 2423678 DOI: 10.1111/J.2042-7158.1986.Tb04601.X  0.205
1975 Tarsy D, Parkes JD, Marsden CD. Letter: Metoclopramide in parkinsonism. Lancet (London, England). 1: 1244-5. PMID 48872 DOI: 10.1016/S0140-6736(75)92237-0  0.205
1997 Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clinical Neuropharmacology. S32-44. PMID 9358193  0.205
1997 Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clinical Neuropharmacology. 20: 95-115. PMID 9099462 DOI: 10.1097/00002826-199704000-00001  0.204
1979 Harrison MJ, Marsden CD, Jenner P. Effect of experimental ischemia on neurotransmitter amines in the gerbil brain. Stroke. 10: 165-8. PMID 35864 DOI: 10.1161/01.STR.10.2.165  0.204
1994 Rinne JO, Daniel SE, Scaravilli F, Harding AE, Marsden CD. Nigral degeneration in neuroacanthocytosis. Neurology. 44: 1629-32. PMID 7936287 DOI: 10.1212/WNL.44.9.1629  0.203
1989 Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 2: 1-8. PMID 3504256 DOI: 10.1002/MDS.870020101  0.203
1973 Brown DM, Hughes BO, Marsden CD, Meadows JC, Spicer B. Some initial animal and human pharmacological studies with benapryzine (BRL 1288). British Journal of Pharmacology. 47: 476-86. PMID 4581246 DOI: 10.1111/j.1476-5381.1973.tb08179.x  0.203
1998 Silva MT, Rose S, Hindmarsh JG, Jenner P, Marsden CD. L-arginine produces NO-independent increases in dopamine efflux in rat striatum. Neuroreport. 9: 149-52. PMID 9592066 DOI: 10.1097/00001756-199801050-00030  0.203
1999 Soonawala N, Bhatia KP, Yeung JH, Quinn NP, Marsden CD. Idiopathic blepharospasm does not lead to a parkinsonian syndrome: results of a questionnaire-based follow-up study. Journal of Neurology. 246: 283-6. PMID 10367696  0.202
1982 Lang AE, Meadows JC, Parkes JD, Marsden CD. Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism. Journal of Neurology, Neurosurgery, and Psychiatry. 45: 823-5. PMID 6982310 DOI: 10.1136/jnnp.45.9.823  0.202
1995 Fernandez A, Jenner P, Marsden CD, De Ceballos ML. Characterization of neurotensin-like immunoreactivity in human basal ganglia: increased neurotensin levels in substantia nigra in Parkinson's disease. Peptides. 16: 339-46. PMID 7784265 DOI: 10.1016/0196-9781(94)00141-3  0.202
1987 De Ceballos ML, Boyce S, Taylor M, Jenner P, Marsden CD. Age-related decreases in the concentration of Met- and Leu-enkephalin and neurotensin in the basal ganglia of rats. Neuroscience Letters. 75: 113-7. PMID 3574764 DOI: 10.1016/0304-3940(87)90085-1  0.202
1989 Rose S, Jenner P, Marsden CD. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 117-25. PMID 3221899 DOI: 10.1002/Mds.870030203  0.201
1983 Rupniak NMJ, Jenner P, Marsden CD. Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats Psychopharmacology. 79: 226-230. PMID 6133305 DOI: 10.1007/Bf00427817  0.201
1984 Rupniak NM, Boyce S, Jenner P, Marsden CD. Interpretation of changes in apomorphine-induced stereotyped behaviour in rats receiving continuous administration of trifluorperazine for 15 months. Neuropharmacology. 23: 893-8. PMID 6148709 DOI: 10.1016/0028-3908(84)90002-9  0.201
1984 Chivers JK, Hall MD, Kelly E, Jenner P, Marsden CD. Dopamine receptor binding sites in the rat superior colliculus. The Journal of Pharmacy and Pharmacology. 36: 484-8. PMID 6146700 DOI: 10.1111/J.2042-7158.1984.Tb04434.X  0.201
1997 Mackenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse (New York, N.Y.). 26: 301-16. PMID 9183819 DOI: 10.1002/(Sici)1098-2396(199707)26:3<301::Aid-Syn11>3.0.Co;2-Y  0.2
1992 Steiger MJ, Pires M, Scaravilli F, Quinn NP, Marsden CD. Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration. Movement Disorders : Official Journal of the Movement Disorder Society. 7: 71-7. PMID 1557069 DOI: 10.1002/mds.870070115  0.2
1988 Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. The Journal of Pharmacy and Pharmacology. 40: 415-21. PMID 2901473 DOI: 10.1111/J.2042-7158.1988.Tb06306.X  0.2
1983 Fleminger S, van de Waterbeemd H, Rupniak NM, Reavill C, Testa B, Jenner P, Marsden CD. Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the rat. The Journal of Pharmacy and Pharmacology. 35: 363-8. PMID 6135774 DOI: 10.1111/j.2042-7158.1983.tb02957.x  0.2
1999 Brown P, Marsden CD. Bradykinesia and impairment of EEG desynchronization in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 423-9. PMID 10348464 DOI: 10.1002/1531-8257(199905)14:3<423::Aid-Mds1006>3.0.Co;2-V  0.198
1989 Eardley I, Quinn NP, Fowler CJ, Kirby RS, Parkhouse HF, Marsden CD, Bannister R. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. British Journal of Urology. 64: 360-2. PMID 2819386 DOI: 10.1111/J.1464-410X.1989.TB06043.X  0.198
1979 Price P, Baxter RCH, Parkes JD, Marsden CD. Opiate antagonists and Parkinson's disease Archives of Neurology. 36: 661. PMID 485903 DOI: 10.1001/ARCHNEUR.1979.00500460095021  0.198
1999 Wills AJ, Brusa L, Wang HC, Brown P, Marsden CD. Levodopa may improve orthostatic tremor: case report and trial of treatment. Journal of Neurology, Neurosurgery, and Psychiatry. 66: 681-4. PMID 10209189 DOI: 10.1136/Jnnp.66.5.681  0.197
1990 Schapira AHV, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in parkinson's disease Journal of Neurochemistry. 55: 2142-2145. PMID 2121905 DOI: 10.1111/J.1471-4159.1990.Tb05809.X  0.197
1994 Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain : a Journal of Neurology. 859-76. PMID 7922471 DOI: 10.1093/BRAIN/117.4.859  0.196
1995 Löschmann PA, Smith LA, Lange KW, Jähnig P, Jenner P, Marsden CD. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology. 109: 49-56. PMID 1365671 DOI: 10.1007/BF02245479  0.196
1977 Meldrum BS, Anlezark GM, Marsden CD. Acute dystonia as an idiosyncratic response to neuroleptics in baboons. Brain : a Journal of Neurology. 100: 313-26. PMID 406964  0.196
1991 Steiger MJ, Quinn NP, Marsden CD. Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 91-2. PMID 2005934 DOI: 10.1002/MDS.870060122  0.196
1993 Turjanski N, Bhatia K, Burn DJ, Sawle GV, Marsden CD, Brooks DJ. Comparison of striatal 18F‐dopa uptake in adult‐onset dystonia‐parkinsonism, Parkinson's disease, and dopa‐responsive dystonia Neurology. 43: 1563-1563. PMID 8351012 DOI: 10.1212/Wnl.43.8.1563  0.196
1991 Steiger MJ, Stocchi F, Carta A, Ruggieri S, Agnoli A, Quinn NP, Marsden CD. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease. Clinical Neuropharmacology. 14: 241-4. PMID 2070364 DOI: 10.1097/00002826-199106000-00007  0.195
1988 El Tayar N, Kilpatrick GJ, Van De Waterbeemd H, Testa B, Jenner P, Marsden C. Interaction of neuroleptic drugs with rat striatal D-1 and D-2 dopamine receptors: a quantitative structure—affinity relationship study European Journal of Medicinal Chemistry. 23: 173-182. DOI: 10.1016/0223-5234(88)90191-2  0.195
1979 Luscombe G, Clow A, Jenner P, Marsden CD. Antagonism by propranolol of central dopamine receptor stimulation is not related to beta-adrenergic blockade. The Journal of Pharmacy and Pharmacology. 31: 355-6. PMID 37316 DOI: 10.1111/J.2042-7158.1979.Tb13522.X  0.194
1976 Pycock C, Milson JA, Tarsy D, Marsden CD. The effects of blocking catecholamine uptake on amphetamine-induced circling behaviour in mice with unilateral destruction of striatal dopaminergic nerve terminals. The Journal of Pharmacy and Pharmacology. 28: 530-2. PMID 7659  0.194
1990 Davis A, Jenner P, Marsden CD. Differential ability of selective and non-selective dopamine agonists to induce climbing in the rat indicates the involvement of both D-1 and D-2 receptors in this behaviour. Psychopharmacology. 100: 19-26. PMID 1967499 DOI: 10.1007/BF02245783  0.194
1981 Kolbe H, Clow A, Jenner P, Marsden CD. Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors Neurology. 31: 434-439. DOI: 10.1212/WNL.31.4_Part_2.434  0.193
1992 Blunt SB, Jenner P, Marsden CD. Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa. Experimental Brain Research. 88: 326-40. PMID 1577107 DOI: 10.1007/Bf02259108  0.193
1991 Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Annals of Neurology. 28: 547-55. PMID 2132742 DOI: 10.1002/Ana.410280412  0.192
1998 Smith LA, Gordin A, Jenner P, Marsden CD. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 12: 935-45. PMID 9399218 DOI: 10.1002/mds.870120616  0.192
1985 Marsden CD. Which motor disorder in Parkinson's disease indicates the true motor function of the basal ganglia? Ciba Foundation Symposium. 107: 225-41. PMID 6568150 DOI: 10.1002/9780470720882.CH12  0.192
1977 Debono AG, Marsden CD, Parkes JD. alpha and beta Dopamine receptors? Acta Neurologica Belgica. 76: 315-7. PMID 1007899  0.192
1991 Collins P, Broekkamp CLE, Jenner P, Marsden CD. Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology. 103: 503-512. PMID 1676528 DOI: 10.1007/Bf02244250  0.192
1990 Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD. Decreased ferritin levels in brain in Parkinson's disease Journal of Neurochemistry. 55: 16-20. PMID 2355217 DOI: 10.1111/J.1471-4159.1990.Tb08814.X  0.192
1987 Cooper DR, Marrel C, van de Waterbeemd H, Testa B, Jenner P, Marsden CD. L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. The Journal of Pharmacy and Pharmacology. 39: 627-35. PMID 2888854 DOI: 10.1111/J.2042-7158.1987.Tb03441.X  0.192
1994 Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AHV, Jenner P, Marsden CD. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease Annals of Neurology. 35: 38-44. PMID 8285590 DOI: 10.1002/Ana.410350107  0.191
1977 Clow A, Elliott PN, Jenner P, Marsden CD, Pycock C. Interactions of substituted benzamide drugs with cerebral dopamine pathways [proceedings]. British Journal of Pharmacology. 60: 268P-269P. PMID 880437  0.191
1985 Pratt JA, Rothwell J, Jenner P, Marsden CD. Myoclonus in the rat induced by p,p'-DDT and the role of altered monoamine function. Neuropharmacology. 24: 361-73. PMID 4022263 DOI: 10.1016/0028-3908(85)90020-6  0.191
1997 Eve DJ, Nisbet AP, Kingsbury AE, Temlett J, Marsden CD, Foster OJ. Selective increase in somatostatin mRNA expression in human basal ganglia in Parkinson's disease. Brain Research. Molecular Brain Research. 50: 59-70. PMID 9406918  0.191
1999 Pearce RKB, Costa S, Jenner P, Marsden CD. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets Journal of Neural Transmission. 106: 663-683. PMID 10907726 DOI: 10.1007/S007020050188  0.191
1984 Leigh PN, Reavill C, Jenner P, Marsden CD. Basal ganglia outflow pathways and circling behaviour in the rat. Journal of Neural Transmission. 58: 1-41. PMID 6418859 DOI: 10.1007/Bf01249122  0.19
1991 Löschmann PA, Smith LA, Lange KW, Jaehnig P, Jenner P, Marsden CD. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets. Psychopharmacology. 105: 303-309. PMID 1686813 DOI: 10.1007/Bf02244422  0.19
1993 Rose S, Jenner P, Marsden CD. Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat. The Journal of Pharmacy and Pharmacology. 45: 725-30. PMID 7901371 DOI: 10.1111/J.2042-7158.1993.Tb07097.X  0.189
1988 Jenner P, Marsden CD. Adaptive changes in brain dopamine function as a result of neuroleptic treatment. Advances in Neurology. 49: 417-31. PMID 2894127  0.188
1984 Kerwin RW, Rupniak NM, Jenner P, Marsden CD. A comparison of the effects of acute and one year's continuous neuroleptic treatment on the release of [3H]glutamate and [3H]acetylcholine from rat striatal slices. Neuroscience. 11: 205-10. PMID 6143281 DOI: 10.1016/0306-4522(84)90224-0  0.188
1988 Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. European Neurology. 54-8. PMID 3322837 DOI: 10.1159/000116193  0.188
2000 Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A, Crabb L, Odin P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Oertel WH, Quinn NP, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain : a Journal of Neurology. 123: 1380-90. PMID 10869050 DOI: 10.1093/Brain/123.7.1380  0.188
1996 Gnanalingham KK, Milkowski NA, Smith LA, Hunter AJ, Jenner P, Marsden CD. Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity. Journal of Neural Transmission. General Section. 101: 65-82. PMID 8695058 DOI: 10.1007/Bf01271546  0.187
1987 Testa B, el Tayar N, Carrupt PA, Van de Waterbeemd H, Kilpatrick GJ, Jenner P, Marsden CD. The influence of aromatic substituents on the binding of substituted benzamides to dopamine D-2 receptors: congruent QSAR and MEP analyses. The Journal of Pharmacy and Pharmacology. 39: 767-8. PMID 2890751 DOI: 10.1111/J.2042-7158.1987.Tb06991.X  0.187
1982 Fleminger S, Jenner P, Marsden CD. Are dopamine receptors present on human lymphocytes Journal of Pharmacy and Pharmacology. 34: 658-663. PMID 6128389 DOI: 10.1111/J.2042-7158.1982.Tb04696.X  0.187
2001 McAuley JH, Corcos DM, Rothwell JC, Quinn NP, Marsden CD. Levodopa reversible loss of the Piper frequency oscillation component in Parkinson's disease Journal of Neurology Neurosurgery and Psychiatry. 70: 471-476. PMID 11254769 DOI: 10.1136/jnnp.70.4.471  0.186
1995 Burn DJ, Rinne JO, Quinn NP, Lees AJ, Marsden CD, Brooks DJ. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study. Brain. 118: 951-958. PMID 7655890 DOI: 10.1093/Brain/118.4.951  0.186
1992 Fernandez A, Ceballos MLd, Jenner P, Marsden CD. Striatal neuropeptide levels in Parkinson's disease patients. Neuroscience Letters. 145: 171-174. PMID 1281532 DOI: 10.1016/0304-3940(92)90014-X  0.186
1991 Steiger MJ, Quinn NP, Toone B, Marsden CD. Off-period screaming accompanying motor fluctuations in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 89-90. PMID 2005932 DOI: 10.1002/MDS.870060120  0.186
1999 Mathen D, Marsden CD, Bhatia KP. SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 874-6. PMID 10495057  0.185
1993 Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. Journal of Neurochemistry. 60: 197-203. PMID 8417140 DOI: 10.1111/J.1471-4159.1993.Tb05838.X  0.185
1989 Dick JP, Rothwell JC, Day BL, Cantello R, Buruma O, Gioux M, Benecke R, Berardelli A, Thompson PD, Marsden CD. The Bereitschaftspotential is abnormal in Parkinson's disease. Brain : a Journal of Neurology. 112: 233-44. PMID 2917279 DOI: 10.1093/Brain/112.1.233  0.185
1988 Jenner P, Marsden CD. Neuroleptic-induced tardive dyskinesia. Acta Psychiatrica Belgica. 87: 566-98. PMID 2897761  0.185
1996 Hurley MJ, Stubbs CM, Jenner P, Marsden CD. Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics. European Journal of Pharmacology. 318: 283-93. PMID 9016916 DOI: 10.1016/S0014-2999(96)00798-4  0.185
1987 Marsden CD, Rothwell JC. The physiology of idiopathic dystonia. Canadian Journal of Neurological Sciences. 14: 521-527. PMID 3315155 DOI: 10.1017/S031716710003804X  0.185
1981 Marsden C, Jenner P. L-dopa's action in parkinson's disease Trends in Neurosciences. 4: 148-150. DOI: 10.1016/0166-2236(81)90049-7  0.184
1998 Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited - Clinical features, natural history, and mortality Movement Disorders. 13: 885-894. PMID 9827611  0.184
1985 Benecke R, Dick J, Rothwell J, Day B, Marsden C. Performance of simultaneous motor acts in normal subjects and in patients with Parkinson's disease Electroencephalography and Clinical Neurophysiology. 61: S41. DOI: 10.1016/0013-4694(85)90187-7  0.184
1991 Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson's disease. Annals of Neurology. 28: 799-804. PMID 2126684 DOI: 10.1002/Ana.410280611  0.184
1976 Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (London, England). 1: 292-6. PMID 55599 DOI: 10.1016/S0140-6736(76)91416-1  0.183
1997 Leiguarda RC, Pramstaller PP, Merello M, Starkstein S, Lees AJ, Marsden CD. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain : a Journal of Neurology. 75-90. PMID 9055799 DOI: 10.1093/BRAIN/120.1.75  0.183
1989 Thompson PD, Dick JP, Day BL, Rothwell JC, Berardelli A, Kachi T, Marsden CD. Electrophysiology of the corticomotoneurone pathways in patients with movement disorders. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 113-7. PMID 3504237 DOI: 10.1002/Mds.870010205  0.183
1975 Costall B, Marsden CD, Naylor RJ, Pycock CJ. Proceedings: Differences in circling responses following electrolytic and 6-hydroxydopamine lesions of the nigro-striatal pathway. British Journal of Pharmacology. 55: 289P-290P. PMID 1238135  0.183
1992 DE CEBALLOS ML, FERNANDEZ A, JENNER P, MARSDEN CD. BASAL GANGLIA NEUROPEPTIDE ALTERATIONS IN PARKINSON??S DISEASE AND CONTROLS BEARING LEWY BODIES Behavioural Pharmacology. 3: 75. DOI: 10.1097/00008877-199204001-00233  0.182
1995 Zeng BY, Jolkkonen J, Jenner P, Marsden CD. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience. 66: 19-28. PMID 7637869 DOI: 10.1016/0306-4522(94)00574-O  0.182
1984 Reavill C, Muscatt S, Leigh PN, Jenner P, Marsden CD. Enhanced GABA function in the angular complex (lateral periaqueductal grey matter and adjacent reticular formation) alters the postural component of striatal- or nigral-derived circling. Experimental Brain Research. 56: 1-11. PMID 6468558 DOI: 10.1007/Bf00237436  0.182
1993 Britton TC, Thompson PD, Day BL, Rothwell JC, Findley LJ, Marsden CD. Modulation of postural wrist tremors by magnetic stimulation of the motor cortex in patients with Parkinson's disease or essential tremor and in normal subjects mimicking tremor. Annals of Neurology. 33: 473-9. PMID 8498824 DOI: 10.1002/ANA.410330510  0.181
1989 Quinn NP, Luthert P, Honavar M, Marsden CD. Pure akinesia due to lewy body Parkinson's disease: a case with pathology. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 85-9. PMID 2538728 DOI: 10.1002/MDS.870040112  0.181
1977 Jenner P, Marsden CD, Pycock C, Reavill C. Lack of serotoninergic involvement in turning behaviour induced by a unilateral lesion of the locus coeruleus in rats [proceedings]. British Journal of Pharmacology. 61: 482P. PMID 563261  0.181
1985 Rupniak NMJ, Jenner P, Marsden CD. Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats Psychopharmacology. 85: 71-79. PMID 2858901 DOI: 10.1007/Bf00427326  0.181
1980 Reavill C, Jenner P, Marsden CD. Metabolite involvement in bromocriptine-induced circling behaviour in rodents. The Journal of Pharmacy and Pharmacology. 32: 278-84. PMID 6103058 DOI: 10.1111/J.2042-7158.1980.Tb12912.X  0.181
1989 Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 69-77. PMID 2973559 DOI: 10.1002/MDS.870010110  0.181
1982 Reavill C, Leigh PN, Jenner P, Marsden CD. Drug-induced circling after unilateral 6-hydroxydopamine lesions of the nigro-striatal pathway is mediated via the midbrain periaqueductal grey and adjacent reticular formation (angular complex). Life Sciences. 29: 2357-65. PMID 6798349 DOI: 10.1016/0024-3205(81)90471-9  0.18
1989 Stewart BR, Jenner P, Marsden CD. Assessment of the muscarinic receptor subtype involved in the mediation of pilocarpine-induced purposeless chewing behaviour. Psychopharmacology. 97: 228-34. PMID 2498932 DOI: 10.1007/BF00442255  0.18
1990 Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease Journal of Neurochemistry. 54: 823-827. PMID 2154550 DOI: 10.1111/J.1471-4159.1990.Tb02325.X  0.18
1992 Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease Annals of Neurology. 32: S82-S87. PMID 1510385 DOI: 10.1002/Ana.410320714  0.18
1995 Haaxma R, van Boxtel A, Brouwer WH, Goeken LN, Denier van der Gon JJ, Colebatch JG, Martin A, Brooks DJ, Noth J, Marsden CD. Motor function in a patient with bilateral lesions of the globus pallidus. Movement Disorders : Official Journal of the Movement Disorder Society. 10: 761-77. PMID 8749996 DOI: 10.1002/Mds.870100610  0.178
1996 Seaton TA, Jenner P, Marsden CD. The isomers of thioctic acid alter C-deoxyglucose incorporation in rat basal ganglia. Biochemical Pharmacology. 51: 983-6. PMID 8651949 DOI: 10.1016/0006-2952(95)02250-3  0.178
1992 Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain : a Journal of Neurology. 333-42. PMID 1606472 DOI: 10.1093/BRAIN/115.2.333  0.178
1983 Lang AE, Marsden CD. Alpha methylparatyrosine and tetrabenazine in movement disorders. Clinical Neuropharmacology. 5: 375-87. PMID 6130839 DOI: 10.1097/00002826-198212000-00005  0.177
1980 Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine. 10: 55-72. PMID 6104342 DOI: 10.1017/S003329170003960X  0.177
1985 Kilpatrick GJ, Jenner P, Marsden CD. Properties of rat striatal D-2 dopamine receptors solubilized with the zwitterionic detergent CHAPS. Journal of Pharmacy and Pharmacology. 37: 320-328. PMID 2862240 DOI: 10.1111/J.2042-7158.1985.Tb05074.X  0.177
1997 Planté-Bordeneuve V, Taussig D, Thomas F, Said G, Wood NW, Marsden CD, Harding AE. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology. 48: 1589-93. PMID 9191771 DOI: 10.1212/wnl.48.6.1589  0.176
1994 Rothwell JC, Vidailhet M, Thompson PD, Lees AJ, Marsden CD. The auditory startle response in progressive supranuclear palsy. Journal of Neural Transmission. Supplementum. 42: 43-50. PMID 7964696 DOI: 10.1007/978-3-7091-6641-3_4  0.176
1983 Luscombe G, Jenner P, Marsden CD. Tryptamine-induced myoclonus in guinea-pigs pretreated with a monoamine oxidase inhibitor indicates pre- and post-synaptic actions of tryptamine upon central indoleamine systems. Neuropharmacology. 21: 1257-65. PMID 6130489 DOI: 10.1016/0028-3908(82)90130-7  0.176
1996 Hurley MJ, Stubbs CM, Jenner P, Marsden CD. Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain. Psychopharmacology. 128: 362-70. PMID 8986007 DOI: 10.1007/S002130050146  0.175
1986 Testa B, Naylor R, Costall B, Jenner P, Marsden CD. Does an endogenous methylpyridinium analogue cause Parkinson's disease? The Journal of Pharmacy and Pharmacology. 37: 679-80. PMID 2867199 DOI: 10.1111/J.2042-7158.1985.Tb05116.X  0.175
1998 Samuel M, Caputo E, Brooks DJ, Schrag A, Scaravilli T, Branston NM, Rothwell JC, Marsden CD, Thomas DGT, Lees AJ, Quinn NP. A study of medial pallidotomy for Parkinson's disease: Clinical outcome, MRI location and complications Brain. 121: 59-75. PMID 9549488 DOI: 10.1093/Brain/121.1.59  0.175
1989 Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain : a Journal of Neurology. 1171-92. PMID 2478251 DOI: 10.1093/brain/112.5.1171  0.175
1979 Reavill C, Jenner P, Leigh N, Marsden CD. Turning behaviour induced by injection of muscimol or picrotoxin into the substantia nigra demonstrates dual GABA components. Neuroscience Letters. 12: 323-8. PMID 460728 DOI: 10.1016/0304-3940(79)96083-X  0.175
1988 Quinn NP, Marion MH, Marsden CD. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations. European Neurology. 105-13. PMID 3322834 DOI: 10.1159/000116204  0.175
1984 Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington' s disease and tardive dyskinesia Journal of Neurology, Neurosurgery and Psychiatry. 47: 844-847. PMID 6236286 DOI: 10.1136/jnnp.47.8.844  0.175
1998 Gu M, Owen AD, Toffa SE, Cooper JM, Dexter DT, Jenner P, Marsden CD, Schapira AH. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. Journal of the Neurological Sciences. 158: 24-9. PMID 9667773 DOI: 10.1016/S0022-510X(98)00095-1  0.174
1986 Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. Clinical Neuropharmacology. 9: 165-81. PMID 3708602 DOI: 10.1097/00002826-198604000-00008  0.174
1989 Dick JP, Benecke R, Rothwell JC, Day BL, Marsden CD. Simple and complex movements in a patient with infarction of the right supplementary motor area. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 255-66. PMID 3504248 DOI: 10.1002/MDS.870010405  0.174
1994 Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain : a Journal of Neurology. 117: 877-97. PMID 7922472  0.173
1992 Brooks DJ, Playford ED, Ibanez V, Sawle GV, Thompson PD, Findley LJ, Marsden CD. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology. 42: 1554-1554. PMID 1641153 DOI: 10.1212/Wnl.42.8.1554  0.173
1974 Marsden CD, Parkes JD, Rees JE. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet (London, England). 2: 1459-62. PMID 4129310 DOI: 10.1016/S0140-6736(73)92729-3  0.173
1971 Parkes JD, Baxter RC, Curzon G, Knill-Jones RP, Knott PJ, Marsden CD, Tattersall R, Vollum D. Treatment of Parkinson's disease with amantadine and levodopa. A one-year study. Lancet. 1: 1083-6. PMID 4102620 DOI: 10.1016/S0140-6736(71)91834-4  0.172
1998 Watts PM, Riedl AG, Douek DC, Edwards RJ, Boobis AR, Jenner P, Marsden CD. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase Neuroscience. 86: 511-519. PMID 9881865 DOI: 10.1016/S0306-4522(97)00649-0  0.172
1989 Coleman RJ, Lange KW, Quinn NP, Loper AE, Bondi JV, Hichens M, Stahl SM, Marsden CD. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 129-38. PMID 2733705 DOI: 10.1002/MDS.870040204  0.172
1983 Rothwell JC, Obeso JA, Traub MM, Marsden CD. The behaviour of the long-latency stretch reflex in patients with Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 46: 35-44. PMID 6842198 DOI: 10.1136/jnnp.46.1.35  0.172
1980 Clow A, Jenner P, Theodorou A, Marsden CD. Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia Advances in Biochemical Psychopharmacology. 24: 53-55. PMID 6105799  0.171
1982 Quinn N, Parkes J, Marsden C, Hardie R, Lees A, Stern G. ON-OFF SYNDROME IN PARKINSON'S DISEASE AND INTRAVENOUS LEVODOPA The Lancet. 320: 992-993. DOI: 10.1016/S0140-6736(82)90199-4  0.171
1995 Inzelberg R, Ridding M, Rothwell J, Marsden C. Changes in motor cortex organization in Parkinson's disease Electroencephalography and Clinical Neurophysiology. 95: P82. DOI: 10.1016/0013-4694(95)93568-R  0.171
1988 Thompson PD, Berardelli A, Rothwell JC, Day BL, Dick JP, Benecke R, Marsden CD. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain : a Journal of Neurology. 111: 223-44. PMID 2967729 DOI: 10.1093/Brain/111.2.223  0.171
1994 Rose S, Jenner P, Marsden CD. Chronic administration does not alter the accumulation of L-dopa into muscle. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 167-72. PMID 8196677 DOI: 10.1002/Mds.870090207  0.171
1980 Schachter M, Bédard P, Debono AG, Jenner P, Marsden CD, Price P, Parkes JD, Keenan J, Smith B, Rosenthaler J, Horowski R, Dorow R. The role of D-1 and D-2 receptors. Nature. 286: 157-9. PMID 7402308 DOI: 10.1038/286157A0  0.171
1992 Vidailhet M, Rothwell JC, Thompson PD, Lees AJ, Marsden CD. The auditory startle response in the Steele-Richardson-Olszewski syndrome and Parkinson's disease. Brain : a Journal of Neurology. 1181-92. PMID 1393510 DOI: 10.1093/brain/115.4.1181  0.171
1986 Gotham AM, Brown RG, Marsden CD. Levodopa treatment may benefit or impair "frontal" function in Parkinson's disease. Lancet (London, England). 2: 970-1. PMID 2877144 DOI: 10.1016/S0140-6736(86)90617-3  0.17
1987 Jenner P, Rose S, Nomoto M, Marsden CD. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects. Advances in Neurology. 45: 183-6. PMID 2881443  0.17
1984 Marsden CD. Motor disorders in basal ganglia disease. Human Neurobiology. 2: 245-50. PMID 6715209  0.17
1992 Steiger MJ, Lledo P, Quinn NP, Marsden CD, Turner P, Jenner PG. Debrisoquine hydroxylation in Parkinson's disease Acta Neurologica Scandinavica. 86: 159-164. PMID 1414226 DOI: 10.1111/j.1600-0404.1992.tb05059.x  0.17
1988 Hong M, Roots EJ, Jenner P, Marsden CD. The effect of long-term treatment with amine-depleting drugs or chlorpromazine on alpha-adrenoreceptors and 5-HT2 receptors in the brain of the rat. Neuropharmacology. 27: 519-27. PMID 2899303 DOI: 10.1016/0028-3908(88)90135-9  0.17
1983 Lang AE, Sheehy MP, Quinn NP, Brincat S, Marsden CD, Parkes D. Lisuride and pergolide in Parkinson's disease. Advances in Neurology. 37: 109-20. PMID 6858769  0.169
1981 Theodorou A, Reavill C, Jenner P, Marsden CD. Kainic acid lesions of striatum and decortication reduce specific [3H]sulpiride binding in rats, so D-2 receptors exist post-synaptically on corticostriate afferents and striatal neurons Journal of Pharmacy and Pharmacology. 33: 439-444. PMID 6115030 DOI: 10.1111/J.2042-7158.1981.Tb13829.X  0.169
1992 Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease Neurology. 42: 2241-2241. PMID 1461374 DOI: 10.1212/Wnl.42.12.2241  0.169
1989 Gibb WR, Lees AJ, Marsden CD. Pathological report of four patients presenting with cranial dystonias. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 211-21. PMID 3193961 DOI: 10.1002/MDS.870030305  0.169
1994 Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease Annals of Neurology. 36: 356-361. PMID 8080243 DOI: 10.1002/Ana.410360306  0.168
1974 Marsden CD, Parkes JD, Rees JE. Letter: Propranolol in Parkinson's disease. Lancet (London, England). 2: 410. PMID 4136980 DOI: 10.1016/S0140-6736(74)91794-2  0.168
1997 Boecker H, Wills AJ, Ceballos-Baumann A, Samuel M, Thomas DG, Marsden CD, Brooks DJ. Stereotactic thalamotomy in tremor-dominant Parkinson's disease: an H2(15)O PET motor activation study. Annals of Neurology. 41: 108-11. PMID 9005873 DOI: 10.1002/Ana.410410118  0.168
1991 Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology. 41: 174-81. PMID 1899474 DOI: 10.1212/WNL.41.2_Part_1.174  0.168
1993 Fletcher NA, Thompson PD, Scadding JW, Marsden CD. Successful treatment of childhood onset symptomatic dystonia with levodopa. Journal of Neurology, Neurosurgery, and Psychiatry. 56: 865-7. PMID 8350101 DOI: 10.1136/jnnp.56.8.865  0.168
2000 Münchau A, Mathen D, Cox T, Quinn NP, Marsden CD, Bhatia KP. Unilateral lesions of the globus pallidus: report of four patients presenting with focal or segmental dystonia. Journal of Neurology, Neurosurgery, and Psychiatry. 69: 494-8. PMID 10990510 DOI: 10.1136/Jnnp.69.4.494  0.168
1979 Schachter M, Blackstock J, Dick JP, George RJ, Marsden CD, Parkes JD. Lisuride in Parkinson's disease. Lancet (London, England). 2: 1129. PMID 91855 DOI: 10.1016/S0140-6736(79)92523-6  0.168
1991 Schapira AH, Holt IJ, Sweeney M, Harding AE, Jenner P, Marsden CD. Mitochondrial DNA analysis in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 294-7. PMID 1979656 DOI: 10.1002/Mds.870050406  0.167
1998 Marsden CD, Olanow CW. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Annals of Neurology. 44: S189-96. PMID 9749592  0.167
1993 Lange KW, Paul GM, Robbins TW, Marsden CD. L-dopa and frontal cognitive function in Parkinson's disease. Advances in Neurology. 60: 475-8. PMID 8420173  0.167
1988 Marsden CD. What do the basal ganglia tell premotor cortical areas? Ciba Foundation Symposium. 132: 282-300. PMID 2962840 DOI: 10.1002/9780470513545.ch17  0.167
1989 Gibb WR, Terruli M, Lees AJ, Jenner P, Marsden CD. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 53-74. PMID 2494438 DOI: 10.1002/Mds.870040109  0.167
1998 Eve DJ, Nisbet AP, Kingsbury AE, Hewson EL, Daniel SE, Lees AJ, Marsden CD, Foster OJ. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Research. Molecular Brain Research. 63: 62-71. PMID 9838046  0.167
1992 Steiger MJ, Quinn NP, Marsden CD. The clinical use of apomorphine in Parkinson's disease. Journal of Neurology. 239: 389-93. PMID 1403022 DOI: 10.1007/BF00812157  0.167
1987 Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease Movement Disorders : Official Journal of the Movement Disorder Society. 2: 73-91. PMID 3504266  0.167
1997 Ceballos-Baumann AO, Sheean G, Passingham RE, Marsden CD, Brooks DJ. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. Brain : a Journal of Neurology. 120: 571-82. PMID 9153120 DOI: 10.1093/Brain/120.4.571  0.166
1996 McNaught KS, Thull U, Carrupt P, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neuroscience Letters. 206: 37-40. PMID 8848276 DOI: 10.1016/0304-3940(96)12419-8  0.166
1995 Vidailhet M, Atchison PR, Stocchi F, Thompson PD, Rothwell JC, Marsden CD. The bereitschaftspotential preceding stepping in patients with isolated gait ignition failure. Movement Disorders : Official Journal of the Movement Disorder Society. 10: 18-21. PMID 7885350 DOI: 10.1002/mds.870100105  0.166
1993 Jahanshahi M, Brown R, Marsden CD. A comparative study of simple and choice reaction time in Parkinson's, Huntington's and cerebellar disease. Journal of Neurology, Neurosurgery, and Psychiatry. 56: 1169-1177. PMID 8229028 DOI: 10.1136/Jnnp.56.11.1169  0.166
1987 Gibb WR, Lees AJ, Wells FR, Barnard RO, Jenner P, Marsden CD. Pathology of MPTP in the marmoset. Advances in Neurology. 45: 187-90. PMID 3103386  0.166
1989 Marsden CD. Slowness of movement in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. S26-37. PMID 2657408 DOI: 10.1002/MDS.870040505  0.166
1986 Dick JP, Rothwell JC, Berardelli A, Thompson PD, Gioux M, Benecke R, Day BL, Marsden CD. Associated postural adjustments in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 49: 1378-85. PMID 3806114 DOI: 10.1136/Jnnp.49.12.1378  0.166
1987 Marsden CD. Parkinson's disease in twins. Journal of Neurology, Neurosurgery, and Psychiatry. 50: 105-6. PMID 3819743 DOI: 10.1136/jnnp.50.1.105  0.165
1996 Bandmann O, Daniel S, Marsden CD, Wood NW, Harding AE. The GTP-cyclohydrolase I gene in atypical parkinsonian patients: a clinico-genetic study. Journal of the Neurological Sciences. 141: 27-32. PMID 8880688 DOI: 10.1016/0022-510x(96)00098-6  0.165
1995 MacKenzie GM, Jenner P, Marsden CD. Effect of 7-nitro indazole on quinolinic acid-induced striatal toxicity in the rat. Neuroreport. 6: 1789-94. PMID 8541483 DOI: 10.1097/00001756-199509000-00020  0.165
1990 Rivest J, Quinn N, Marsden CD. Dystonia in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy Neurology. 40: 1571-1578. PMID 2215950 DOI: 10.1212/WNL.40.10.1571  0.165
1997 Gu M, Gash MT, Cooper JM, Wenning GK, Daniel SE, Quinn NP, Marsden CD, Schapira AH. Mitochondrial respiratory chain function in multiple system atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. 12: 418-22. PMID 9159739 DOI: 10.1002/mds.870120323  0.165
1993 Atchison PR, Thompson PD, Frackowiak RS, Marsden CD. The syndrome of gait ignition failure: a report of six cases. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 285-92. PMID 8341292 DOI: 10.1002/mds.870080306  0.165
1986 Grandas Perez FJ, Jenner PG, Nomoto M, Stahl S, Quinn NP, Parkes JD, Critchley P, Marsden CD. (+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease. Lancet (London, England). 1: 906. PMID 2870368 DOI: 10.1016/S0140-6736(86)91004-4  0.165
1976 Mindham RH, Marsden CD, Parkes JD. Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychological Medicine. 6: 23-33. PMID 778880 DOI: 10.1017/S0033291700007467  0.165
1987 Waters CM, Hunt SP, Jenner P, Marsden CD. Localization of neurotensin receptors in the forebrain of the common marmoset and the effects of treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research. 412: 244-53. PMID 3038264 DOI: 10.1016/0006-8993(87)91130-9  0.165
1989 Coleman RJ, Temlett JA, Quinn NP, Stahl SM, Marsden CD. A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations. Clinical Neuropharmacology. 12: 37-45. PMID 2565765 DOI: 10.1097/00002826-198902000-00005  0.164
1986 Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology. 88: 403-19. PMID 2871578 DOI: 10.1007/Bf00178501  0.164
1994 Marsden CD. Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 57: 672-81. PMID 7755681 DOI: 10.1136/jnnp.57.6.672  0.164
1992 Marsden CD. Parkinson's disease. Postgraduate Medical Journal. 68: 538-43. PMID 1437950 DOI: 10.1136/pgmj.68.801.538  0.164
1990 Marsden CD. Parkinson's disease. Lancet (London, England). 335: 948-52. PMID 1691427 DOI: 10.1016/0140-6736(90)91006-V  0.164
1979 Price P, Parkes JD, Marsden CD. Tiapride in Parkinson's disease. Lancet (London, England). 2: 1106. PMID 82131 DOI: 10.1016/S0140-6736(78)91850-0  0.164
1986 Marsden CD, Sandler M. The MPTP story: an introduction. Journal of Neural Transmission. Supplementum. 20: 1-3. PMID 3091759  0.163
1985 Dewar D, Jenner P, Marsden CD. Behavioural effects in rats of unilateral and bilateral injections of opiate receptor agonists into the globus pallidus. Neuroscience. 15: 41-6. PMID 2989729 DOI: 10.1016/0306-4522(85)90121-6  0.163
1982 Lang AE, Quinn N, Brincat S, Marsden CD, Parkes JD. Pergolide in late-stage Parkinson disease. Annals of Neurology. 12: 243-7. PMID 6753730 DOI: 10.1002/ANA.410120305  0.163
1984 Quinn NP, Lang AE, Thompson C, Brincat S, Marsden CD, Parkes JD. Pergolide in the treatment of Parkinson's disease. Advances in Neurology. 40: 509-13. PMID 6695628  0.163
1998 Playford ED, Passingham RE, Marsden CD, Brooks DJ. Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 309-18. PMID 9539346 DOI: 10.1002/Mds.870130218  0.163
1998 Jolkkonen J, Jenner P, Marsden CD. Glutamatergic regulation of striatal peptide gene expression in rats. Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 10: 187-98. PMID 9620062 DOI: 10.1007/BF02251230  0.162
1989 Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 65-8. PMID 3504233 DOI: 10.1002/MDS.870010109  0.162
1995 Collins P, Broekkamp CL, Jenner P, Marsden CD. Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains. Psychopharmacology. 112: 437-44. PMID 7871054 DOI: 10.1007/Bf02244891  0.162
1988 Willoughby J, Glover V, Sandler M, Albanese A, Jenner P, Marsden CD. Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity Neuroscience Letters. 90: 100-106. PMID 3137508 DOI: 10.1016/0304-3940(88)90794-X  0.162
1985 Reavill C, Jenner P, Marsden CD. Gamma-aminobutyric acid and basal ganglia outflow pathways. Ciba Foundation Symposium. 107: 164-76. PMID 6094124 DOI: 10.1002/9780470720882.ch9  0.162
1999 Schrag A, Samuel M, Caputo E, Scaravilli T, Troyer M, Marsden CD, Thomas DG, Lees AJ, Brooks DJ, Quinn NP. Unilateral pallidotomy for Parkinson's disease: results after more than 1 year. Journal of Neurology, Neurosurgery, and Psychiatry. 67: 511-7. PMID 10486400 DOI: 10.1136/Jnnp.67.4.511  0.162
1999 Kingsbury AE, Marsden CD, Foster OJ. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 206-18. PMID 10091611  0.162
2016 Thongsaard W, Sangpayap R, Marsden C. Chronic Effect of Thunbergia laurifolia Extract and Cocaine in Rats Using Behavior Model of Addiction. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet. S48-52. PMID 26817209  0.162
1996 Berardelli A, Hallett M, Rothwell JC, Agostino R, Manfredi M, Thompson PD, Marsden CD. Single-joint rapid arm movements in normal subjects and in patients with motor disorders. Brain : a Journal of Neurology. 119: 661-74. PMID 8800955 DOI: 10.1093/Brain/119.2.661  0.162
1976 Marsden CD. ADVANCES IN NEUROLOGY Vol. 3. PROGRESS IN THE TREATMENT OF PARKINSONISM Journal of Neurology, Neurosurgery & Psychiatry. 39: 101-101. DOI: 10.1136/JNNP.39.1.101-A  0.162
1974 Parkes JD, Marsden CD, Rees JE, Curzon G, Kantamaneni BD, Knill-Jones R, Akbar A, Das S, Kataria M. Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa. The Quarterly Journal of Medicine. 43: 49-61. PMID 4822972  0.161
1998 Berardelli A, Rothwell JC, Hallett M, Thompson PD, Manfredi M, Marsden CD. The pathophysiology of primary dystonia. Brain : a Journal of Neurology. 121: 1195-212. PMID 9679773 DOI: 10.1093/Brain/121.7.1195  0.161
1972 Marsden C. Parkinson's disease and the parkinsonian syndrome Journal of Psychosomatic Research. 16: 138. DOI: 10.1016/0022-3999(72)90057-8  0.161
1989 Aubby D, Saggu HK, Jenner P, Quinn NP, Harding AE, Marsden CD. Leukocyte glutamate dehydrogenase activity in patients with degenerative neurological disorders. Journal of Neurology, Neurosurgery, and Psychiatry. 51: 893-902. PMID 3204397 DOI: 10.1136/jnnp.51.7.893  0.161
1993 Dexter DT, Sian J, Jenner P, Marsden CD. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia Advances in Neurology. 60: 273-281. PMID 8420143  0.161
1992 Dexter DT, Ward RJ, Wells FR, Daniel SE, Lees AJ, Peters TJ, Jenner P, Marsden CD. α-Tocopherol levels in brain are not altered in Parkinson's disease Annals of Neurology. 32: 591-593. PMID 1456747 DOI: 10.1002/ana.410320420  0.161
1994 MacKenzie GM, Rose S, Bland-Ward PA, Moore PK, Jenner P, Marsden CD. Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole. Neuroreport. 5: 1993-6. PMID 7531007 DOI: 10.1097/00001756-199410000-00039  0.161
1987 Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Advances in Neurology. 45: 493-6. PMID 3548262  0.161
1992 Stocchi F, Ruggieri S, Carta A, Ryatt J, Quinn N, Jenner P, Marsden CD, Agnoli A. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 7: 249-56. PMID 1620143 DOI: 10.1002/Mds.870070311  0.161
1985 Day BL, Dick JP, Marsden CD. Patients with Parkinson's disease can employ a predictive motor strategy. Journal of Neurology, Neurosurgery, and Psychiatry. 47: 1299-306. PMID 6512550 DOI: 10.1136/jnnp.47.12.1299  0.161
1999 Pramstaller PP, Salerno A, Bhatia KP, Prugger M, Marsden CD. Primary central nervous system lymphoma presenting with a parkinsonian syndrome of pure akinesia. Journal of Neurology. 246: 934-8. PMID 10552241  0.16
1992 Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology. 107: 394-404. PMID 1615139 DOI: 10.1007/BF02245167  0.16
1980 Guiloff RJ, George RJ, Marsden CD. Reversible supranuclear ophthalmoplegia associated with Parkinsonism. Journal of Neurology, Neurosurgery, and Psychiatry. 43: 552-4. PMID 7205300 DOI: 10.1136/jnnp.43.6.552  0.16
1993 Vidailhet M, Stocchi F, Rothwell JC, Thompson PD, Day BL, Brooks DJ, Marsden CD. The Bereitschaftspotential preceding simple foot movement and initiation of gait in Parkinson's disease. Neurology. 43: 1784-8. PMID 8414032 DOI: 10.1212/Wnl.43.9.1784  0.16
1998 Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 104: 661-77. PMID 9444566 DOI: 10.1007/Bf01291884  0.16
1995 Ceballos-Baumann AO, Passingham RE, Marsden CD, Brooks DJ. Motor reorganization in acquired hemidystonia. Annals of Neurology. 37: 746-57. PMID 7778848 DOI: 10.1002/Ana.410370608  0.16
1992 Lange KW, Javoy-Agid F, Agid Y, Jenner P, Marsden CD. Brain muscarinic cholinergic receptors in Huntington's disease. Journal of Neurology. 239: 103-4. PMID 1532417 DOI: 10.1007/Bf00862983  0.16
1991 Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia Brain. 114: 1953-1975. PMID 1832073 DOI: 10.1093/Brain/114.4.1953  0.16
1992 Sawle GV, Bloomfield PM, Björklund A, Brooks DJ, Brundin P, Leenders KL, Lindvall O, Marsden CD, Rehncrona S, Widner H. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Annals of Neurology. 31: 166-73. PMID 1575455 DOI: 10.1002/ana.410310207  0.159
1984 Cowan JMA, Dick JPR, Day BL, Rothwell JC, Thompson PD, Marsden CD. Abnormalities in central motor pathway conduction in multiple sclerosis. The Lancet. 324: 304-307. PMID 6146860 DOI: 10.1016/S0140-6736(84)92683-7  0.159
1993 Bhatia K, Daniel SE, Marsden CD. Orofacial dystonia and rest tremor in a patient with normal brain pathology. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 361-2. PMID 8341303 DOI: 10.1002/MDS.870080320  0.158
1993 Pastor MA, Day BL, Marsden CD. Vestibular induced postural responses in Parkinson's disease. Brain : a Journal of Neurology. 1177-90. PMID 8221054 DOI: 10.1093/BRAIN/116.5.1177  0.158
1982 Lang AE, Sheehy MP, Marsden CD. Anticholinergics in adult-onset focal dystonia. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 9: 313-9. PMID 7116238 DOI: 10.1017/S0317167100044139  0.158
1980 Rothwell JC, Traub MM, Marsden CD. Primary writing tremor. Journal of Neurology, Neurosurgery, and Psychiatry. 42: 1106-14. PMID 160444 DOI: 10.1136/jnnp.42.12.1106  0.158
1974 Marsden CD. PROGRESS IN THE TREATMENT OF PARKINSONISM Journal of Neurology, Neurosurgery & Psychiatry. 37: 1394-1394. DOI: 10.1136/JNNP.37.12.1394  0.158
1978 Chadwick D, Hallett M, Jenner P, Marsden CD. 5-hydroxytryptophan-induced myoclonus in guinea pigs. A physiological and pharmacological investigations. Journal of the Neurological Sciences. 35: 157-65. PMID 304885 DOI: 10.1016/0022-510X(78)90108-9  0.158
1991 Rose S, Jenner P, Marsden CD. Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment. Journal of Pharmacy and Pharmacology. 43: 325-330. PMID 1680174 DOI: 10.1111/J.2042-7158.1991.Tb06698.X  0.157
1994 Harwood G, Hierons R, Fletcher NA, Marsden CD. Lessons from a remarkable family with dopa-responsive dystonia. Journal of Neurology, Neurosurgery, and Psychiatry. 57: 460-3. PMID 8163996 DOI: 10.1136/jnnp.57.4.460  0.157
1999 Riedl AG, Watts PM, Edwards RJ, Schulz-Utermoehl T, Boobis AR, Jenner P, Marsden CD. Expression and localisation of CYP2D enzymes in rat basal ganglia. Brain Research. 822: 175-91. PMID 10082895 DOI: 10.1016/S0006-8993(99)01113-0  0.157
1994 Jolkkonen J, Jenner P, Marsden CD. GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment. Neuroscience Letters. 180: 273-276. PMID 7535410 DOI: 10.1016/0304-3940(94)90537-1  0.157
1985 Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet (London, England). 2: 1262-5. PMID 6150288 DOI: 10.1016/S0140-6736(84)92807-1  0.157
1989 Lange KW, Wells FR, Rossor MN, Jenner P, Marsden CD. Cortical muscarinic receptors in demented patients with Alzheimer's disease or Parkinson's disease. British Journal of Pharmacology. 98: 817P. PMID 2611524  0.157
1998 MARSDEN CD. Pigmentation in the nucleus substantiae nigrae of mammals. Journal of Anatomy. 95: 256-61. PMID 13767161  0.156
2000 Lapiz MD, Mateo Y, Parker T, Marsden C. Effects of noradrenaline depletion in the brain on response on novelty in isolation-reared rats. Psychopharmacology. 152: 312-20. PMID 11105942 DOI: 10.1007/s002130000534  0.156
1990 Truong DD, Harding AE, Scaravilli F, Smith SJ, Morgan-Hughes JA, Marsden CD. Movement disorders in mitochondrial myopathies. A study of nine cases with two autopsy studies. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 109-17. PMID 2325672 DOI: 10.1002/mds.870050204  0.156
1987 Dexter DT, Boyce S, Jenner P, Marsden CD. Chronic trifluoperazine treatment does not induce lipid peroxidation in the rat cortex Neuroscience Letters. 76: 368-371. PMID 3587766 DOI: 10.1016/0304-3940(87)90431-9  0.156
1976 Marsden CD. ADVANCES IN NEUROLOGY Vol. 5. SECOND CANADIAN-AMERICAN CONFERENCE ON PARKINSON'S DISEASE Journal of Neurology, Neurosurgery & Psychiatry. 39: 101-101. DOI: 10.1136/JNNP.39.1.101-B  0.156
1987 Thompson PD, Day BL, Rothwell JC, Dick JPR, Cowan JMA, Asselman P, Griffin GB, Sheehy MP, Marsden CD. The interpretation of electromyographic responses to electrical stimulation of the motor cortex in diseases of the upper motor neurone Journal of the Neurological Sciences. 80: 91-110. PMID 3039071 DOI: 10.1016/0022-510X(87)90224-3  0.156
1989 Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease Journal of Neurochemistry. 52: 1830-1836. PMID 2723638 DOI: 10.1111/J.1471-4159.1989.Tb07264.X  0.155
1992 Soliveri P, Brown R, Jahanshahi M, Marsden CD. Effect of practice on performance of a skilled motor task in patients with Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 55: 454-460. PMID 1619411 DOI: 10.1136/Jnnp.55.6.454  0.155
1996 Seaton TA, Jenner P, Marsden CD. Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. Biochemical Pharmacology. 52: 1657-1663. PMID 8986127 DOI: 10.1016/S0006-2952(96)00452-2  0.155
Hide low-probability matches.